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Systemic lupus erythematosus (SLE) is associated with increased risk of cardiovascular 
disease; up to 50-fold in young women. Cardiovascular risk algorithms do not take SLE into 
account, nor are there biomarkers available to stratify patient risk. This project aimed to 
consider the role of endothelial microvesicles (EMVs) as biomarkers of cardiovascular risk 
and also as effectors through their miRNA content. 
To do so, EMVs were isolated and quantified from patient plasma by flow cytometry, before 
being correlated with QRISK cardiovascular risk scores and patient data. Key miRNAs were 
identified by data mining, and their abundance was determined in the vesicular fraction of 
patient plasma by quantitative PCR (qPCR). Thus an SLE miRNA panel was characterised. 
Finally, the effects of miRNA overexpression in endothelial cells were probed by developing 
miRNA constructs and lentiviral vectors through Gateway® cloning prior to functional tests. 
This revealed that patients with SLE demonstrated elevated QRISK3 scores, as well as 
markers of inflammation and cardiovascular risk, compared to controls. They were also 
found to have increased numbers of EMVs, which were further associated with 
cardiovascular risk. Five miRNAs were chosen to be studied and lentiviral vectors were 
successfully generated to model their overexpression. Of these, miR-126-3p was elevated 
in patients with an SLE flare, where it was associated with musculoskeletal symptoms, and 
caused a glycolytic shift when overexpressed in endothelial cells; miR-3148 was also 
elevated in SLE. MiR-93-5p, miR-320a and miR-30d-5p were reduced in SLE, but their 
overexpression resulted in impaired angiogenic tube formation in vitro, and they were 
associated with measures of fatigue in patients. 
This project supports the use of EMVs as biomarkers of cardiovascular risk in SLE, where 
they reflect disease activity and cardiovascular involvement. The identification of a miRNA 
panel further refines patient stratification and allows future identification of functional 








1.1. Cardiovascular Disease 
 
1.1.1. The Societal Impact of Cardiovascular Disease 
According to the British Heart Foundation, approximately 7 million people in the UK are 
currently living with cardiovascular disease (CVD). Within the UK, CVD accounts for 25% of 
all deaths, meaning around 420 people die from this disease each day(1). Furthermore, 
CVD is the greatest cause of death globally. However, this is unequally distributed such that 
over 75% of these global deaths occur in countries of low or middle income(2); Manchester 
carries the highest rate of premature deaths due to CVD in the UK (140.7 deaths/100,000 
population; Figure 1.1), which is substantially higher than more affluent areas(1). This is 
likely due to a number of lifestyle factors including diet, exercise and smoking – on average, 
19.3% of Greater Manchester residents smoke compared to 17.2% across England and 
16.2% in the more affluent South East(3) – as well as the level of governmental support and 
socioeconomic factors. Indeed, the prevalence of CVD places a huge burden on the 
economy, with UK healthcare costs of £9 billion per year. Furthermore, CVD greatly impacts 
quality of life, thus when disability and other costs are taken into account, this figure is 







Figure 1.1: Premature mortality from CVD in the UK. This heatmap shows premature death 
rates grouped by local authority. ‘Premature’ defined as <75 years. Image courtesy of British 
Heart Foundation (BHF/University of Birmingham calculated rates in partnership with UK 









1.1.2. The Clinical Problem of CVD and its Co-Morbidities 
‘Cardiovascular disease’ is an umbrella term, encompassing a number of disorders of the 
heart and blood vessels. Examples of cardiac presentations include coronary heart disease, 
congestive heart failure, rheumatic and congenital heart disease, while vascular diseases 
range from stroke and cerebrovascular disease to peripheral arterial disease, as well as 
deep vein thrombosis and pulmonary embolism. Hypertension may also be considered a 
CVD. Although CVDs cover a spectrum of conditions, they often share similar risk factors or 
pathologies. A common link is that of damage and inflammation, whether limited to a 
certain vascular bed or spread throughout the circulatory system. Development of 
atherosclerosis or changes in blood clotting can also both predispose to acute events such 
as myocardial infarction or stroke, and can propagate chronic CVDs. Generally, common 
CVDs are associated with the same risk factors of poor diet/obesity, sedentary lifestyle, 
smoking and drinking excessive amounts of alcohol. Others, such as rheumatic heart 
disease and vasculitis, are related to the presence or history of other diseases. Further 
information can be found on the respective websites of the British Heart Foundation 
(https://www.bhf.org.uk/) and the World Health Organisation 
(https://www.who.int/cardiovascular_diseases/en/).  
Within this text, the use of ‘CVD’ will refer to conditions of the cardiovascular system 
involving damage, inflammation and increased risk of acute events. Although CVDs are 
characterised by multiple functional and physiological changes throughout the vasculature, 
this text will focus on dysfunction within the endothelial layer, the mechanisms of which 
will be further discussed.  
 
 
1.1.3. The Vascular Endothelium in CVD 
The structure of an artery is trilaminar, being composed of, in order of lumen outwards, a 
tunica intima, tunica media and an adventitia. The tunica intima comprises a monolayer of 
endothelial cells atop a collagen-rich basement membrane, the contents of which are 
produced by the smooth muscle cells of the tunica media layer below(4). Thus, the 




interface between blood and vasculature, such as prevention of inappropriate coagulation 
through surface molecules or modulation of vascular tone e.g. via release of nitric oxide 
(NO). It is therefore unsurprising that dysfunction of the vascular endothelium could 
support development of cardiovascular disease(5). 
 
 
1.1.3.1. Endothelial Activation and Dysfunction 
Endothelial dysfunction is typically characterised by reduced activity or production of NO 
by the endothelial cells, for instance due to oxidative stress, resulting in impaired vascular 
reactivity(6). The reduction in vasodilation can be detected non-invasively by flow 
mediated dilatation (FMD), a widely used method to measure endothelial dysfunction in 
the clinic, particularly in patients with rheumatological disorders(7). Endothelial 
dysfunction is often the first indication of future atherosclerotic changes, the development 
of which may then lead to cardiovascular disease(7-9).  
The formation of an atherosclerotic plaque is depicted in figure 1.2. Briefly, low density 
lipoproteins (LDL) are deposited into the intimal layer, over time forming fatty streaks along 
the vessel wall.  Monocytes are recruited from the blood into the intima, where they 
differentiate into macrophages and, further, foam cells via uptake of the oxidised LDL. The 
subsequent release of reactive oxygen species (ROS), growth factors and inflammatory 
cytokines, such as tumour necrosis factor-α (TNFα) and interferons, causes the 
proliferation of vascular smooth muscle cells (VSMCs), which then increase production of 
extracellular matrix(7-9). The result is a fibrous cap covering a necrotic core rich in lipids 
and cellular debris, accompanied by inflammation and calcification. If this is left to 
continue, extensive matrix remodelling and further infiltration by inflammatory cells 
decreases plaque stability and can result in rupture or erosion. The plaque contents are 
extremely thrombogenic, inciting thrombus formation, vessel occlusion and clinical 
symptoms of CVD(8, 9).   
The terms ‘endothelial dysfunction’ and ‘endothelial activation’ are sometimes, incorrectly, 




atherosclerosis and so both may be used in this text, depending on the angle of 
investigation. While endothelial dysfunction describes abnormalities of vascular tone prior 
to atherogenesis, endothelial activation refers to the expression of cell-surface adhesion 
molecules, which are responsible for leukocyte recruitment and downstream propagation 
of inflammation(6, 9). It may be said that, in the process of atherogenesis, activation occurs 
before dysfunction and this has been indicated in figure 1.2. Yet it is also understood that 
NO suppresses endothelial activation, reinforcing the intricate relationships that hold 










Figure 1.2: Pathological mechanisms in atherogenesis. Long term exposure to 
cardiovascular risk factors leads to intimal LDL retention and oxidation. Upregulated 
expression of adhesion molecules supports recruitment and transmigration of leukocytes 
such as monocytes and T cells. Monocytes mature into macrophages within the intima, 
where they ingest oxidised LDL (oxLDL), becoming foam cells. Release of inflammatory 
factors such as cytokines, matrix metalloproteinases (MMPs) and reactive oxygen species 
by leukocytes contributes to development of highly inflammatory environment. Endothelial 
microvesicles are further released from the endothelium into the circulation. This 
environment stimulates vascular smooth muscle cell (VSMC) proliferation, migration and 
production of extracellular matrix, which forms a fibrous cap. VSMCs can also undergo 
calcification, reducing arterial elasticity. Cellular apoptosis causes build-up of a necrotic, 
lipid-rich core underneath the cap. Extensive matrix remodelling (such as through MMPs) 
and increased angiogenesis stimulated by hypoxia threaten plaque stability and can result 
in rupture, triggering activation of platelets and formation of a thrombus. IFN-γ, interferon-
gamma; IL, interleukin; MCP-1, monocyte chemoattractant protein; M-CSF, macrophage 
colony-stimulating factor; SR-A, scavenger receptor A; TGF-β, transforming growth factor-
beta; Th1, T helper cell type 1; Treg, T regulatory cell; VEGF, vascular endothelial growth 
factor. Adapted from Wilck and Ludwig (2014). 
 
 
1.1.3.2. Risk Factors for Endothelial Dysfunction and CVD 
Atherosclerosis is more likely to develop in ‘atheroprone’ regions such as arterial 
bifurcations and branches. This is due to a region-specific change in blood flow from 
pulsatile and unidirectional to oscillatory or turbulent(12). This difference in shear stress 
triggers alternative signalling pathways by the endothelial cells and a phenotypic switch 
that increases permeability and monocyte attachment, as is elegantly reviewed by Zhou et 
al. (2014). Indeed, endothelial cells at these regions undergo endothelial to mesenchymal 
transition, which is associated with vascular fibrosis and atherogenesis(13). Furthermore, 
changes in shear stress are associated with alterations in the endothelial glycocalyx, 
resulting in impaired mechanosensing and signal transduction(14). Therefore the 




leukocytes, and phenotypic changes linked to development of atherosclerosis(12). 
Accordingly, changes in shear stress can predict plaque development(15, 16). Perturbations 
in blood pressure can further increase stress and predispose to vascular remodelling and 
endothelial dysfunction, which, as has been discussed, then results in reduced vascular 
reactivity and propagation of hypertension. Thus hypertension is often noted as a risk 
marker for CVD, and is a primary treatment target(4, 12). 
Other common risk markers pertain to diet and associated obesity.  The role of lipids, 
particularly LDL cholesterol, is described in the previous section and is well documented, 
with implications in foam cell accumulation, vascular smooth muscle proliferation and 
inflammation, especially when oxidised(17-19). While LDL is associated with atherogenesis, 
high density lipoproteins (HDL) show the inverse relationship(20). The mechanisms 
underpinning this are still under investigation, however HDL appears to have a crucial role 
in removal of excess cholesterol, as well as anti-oxidant, anti-inflammatory and endothelial-
protective functions(21-24). As such, HDL:LDL ratios may be used diagnostically to predict 
cardiovascular risk and therapeutic interventions aimed at restoring lipid balance, such as 
statins, are often prescribed to high risk individuals(20, 24). Circulating triglyceride levels 
may additionally be utilised in cardiovascular risk prediction as they appear to follow a 
positive correlation; whether this is a causal relationship or triglyceride levels solely reflect 
LDL status has historically been debated(25). Nevertheless, recent studies of individuals 
with genetic variations affecting triglycerides, including lipoprotein lipase, have begun to 
yield fascinating causal links between triglycerides and CVD(26, 27).  
Hyperglycaemia and associated insulin resistance is another major risk factor for CVD; 
elevated fasting glucose level is linked to increased risk of death, including from CVD(28). 
Hyperglycaemia affects the endothelium through formation of advanced glycation end 
products (AGEs), which bind to endothelial receptors and support dysfunction via induction 
of oxidative stress and reduced NO production(29, 30). Consequently, patients with 
diabetes develop accelerated atherosclerosis and impaired vasodilator function(30, 31). 
A third aspect of diet that increases cardiovascular risk is salt intake. Excessive salt intake 
is linked to hypertension, which then predisposes to endothelial dysfunction, as discussed 




chloride may also directly affect the endothelium, independently of hypertension, through 
ROS production and impaired vasodilation(33, 34).   
In contrast, a non-modifiable risk factor for CVD is age, which is arguably the strongest 
predictor of cardiovascular health. As we age, the vasculature undergoes a series of 
changes that render it more susceptible to damage and dysfunction. Arteries lose elasticity 
and vasoreactivity through a combination of hypertrophy, extracellular matrix deposition 
and NO reduction(35, 36); they also may become subject to eutrophic remodelling, 
supporting the development of hypertension(37). Furthermore, the aged endothelium 
shows compromised barrier function and increased cytokine production, boosting the 
inflammatory environment; the combination of inflammation, endothelial dysfunction and 
vascular stiffening hastens atherogenesis(36, 38, 39).  
A final risk factor for atherosclerosis is the presence and extent of inflammation; elevated 
risk of CVD has been well documented in autoimmune conditions characterised by chronic 
inflammation, which is associated with endothelial dysfunction. Large quantities of 
inflammatory cytokines such as TNFα are present in the circulation of these patients(8, 40). 
TNFα reduces NO bioavailability as well as stimulating production of further inflammatory 
mediators(40, 41), the result of which is an activated endothelium expressing chemotactic 
and adhesion molecules, and increased atherosclerosis(8, 42). The role of infiltrating 
leukocytes in atherosclerosis is introduced in section 1.1.3.1., and can be altered by the 
specific cell subtypes present. For example, helper Th1 and Th17 T cells have been linked 
to deleterious effects on the vasculature whereas regulatory (Treg) T cells appear to be 
protective(43, 44). These cells often demonstrate a ‘skew’ in autoimmune inflammatory 
conditions, with pro-inflammatory subsets playing a greater role(44-46). Furthermore, 
increased numbers of patrolling monocyte subsets are also found in these conditions, 
predisposing to development of subclinical atherosclerosis(47, 48). The connections 
between inflammation and CVD have also opened the door to new biomarkers to quantify 
cardiovascular risk, such as high-sensitivity C-reactive protein (hsCRP), an acute phase 
protein released under inflammatory conditions(49). By improving understanding and 
knowledge of the processes underlying endothelial dysfunction and atherosclerosis in 
conditions with high risk of CVD, novel biomarkers and therapeutic targets can be identified 




inflammatory disorder that carries a high cardiovascular risk is systemic lupus 
erythematosus (SLE), which is an excellent disease model to study endothelial damage and 
vascular aging and is discussed further below.  
 
 
1.2. Systemic Lupus Erythematosus 
 
1.2. The Impact of SLE 
SLE is an autoimmune condition characterised by autoantibody production, immune 
complex deposition and disseminated inflammation. Patients are predominantly female 
and the disease is more prevalent in those with African or Asian heritage(50-52). Incidence 
and prevalence varies across the globe(51), although UK figures estimated a prevalence of 
97.04/100,000 in 2012(50). SLE is a complex disease with individual variations and a 
significant delay in diagnosis. A 2014 LUPUS UK study involving 2527 participants found 
that 72.7% of patients struggled to carry out daily activities and only 15% were in full time 
employment, highlighting the impact of this condition on quality of life(52). 
 
 
1.2.1.1. The Symptoms of SLE are Heterogeneous and Patient-Specific 
The same LUPUS UK study stated that 53.8% of patients frequently suffered between 6-10 
different physical symptoms, highlighting the heterogeneity and systemic nature of the 
disease. The most common symptoms were weakness, fatigue and joint swelling, with 
50%+ also experiencing poor circulation, back pain and flu-like symptoms/night sweats(52). 
Another UK study described musculoskeletal, mucocutaneous and psychological 
symptoms, as well as fatigue, as most commonly recorded prior to diagnosis 
(arthritis/arthralgia, rash and depression respectively). The mean age at diagnosis in this 
study was found to be 49.4 years, with a mean wait time of 26.4 months following first 
musculoskeletal symptoms, although this increased to 6.4 years in some patients(53). The 




and establish the necessity of tailored treatment dependent on the particular constellation 




Figure 1.3: SLE affects multiple organ systems. Due to the presence of antinuclear 
antibodies and deposition of immune complexes, virtually any organ system can be affected 








1.2.1.2. Autoimmunity in SLE 
Autoantibodies are a hallmark of SLE and contribute to immune complex deposition and 
activation of the immune response. Immunoglobulin G (IgG) is the predominant isotype of 
autoantibody, and is commonly reactive against the patients’ own double stranded DNA 
(dsDNA) but may also target complement factors, endothelial cells, histones, nucleosomal 
material and ribosomal P protein. The autoantibody profile of a patient is often used 
diagnostically to confirm disease but also contributes to the disease through formation of 
immune complexes. Tissue damage causes further release of DNA and associated factors, 
thus restarting the cycle(54, 55). 
Autoantibodies can propagate SLE in a number of ways. For example, anti-dsDNA 
antibodies activate the NLRP3 inflammasome in monocytes and macrophages, increasing 
the production of inflammatory cytokines such as interleukin-1 (IL-1)(56). The formation of 
immune complexes containing autoantibodies is a key process in the pathology of SLE; 
these complexes are deposited, and become lodged, within capillaries and other tissues 
where they cause damage and occlusion. Furthermore, the complexed antibodies are able 
to activate complement, and recruit and activate leukocytes, particularly neutrophils, while 
offering additional antigens for recognition by immune cells(57).  
Although IgG isotypes may be elevated in SLE, other antibody classes are reduced, such as 
IgM(55, 58). Depleted levels of IgM are associated with presence of autoimmunity and 
inflammation, although autoreactive IgM are also observed(58). In particular, IgM 
antibodies targeting phosphorylcholine promote polarisation of anti-inflammatory Treg 
cells(59), and confer athero- and renal protection(60, 61).  
 
 
1.2.1.3. The Inflammatory Environment of SLE 
As described in section 1.2.1.2, propagation of tissue damage releases further autoantigens 
such as dsDNA. Interestingly, patients with SLE demonstrate inadequate clearance of 
apoptotic debris, which is related to reduced activity of DNase(62, 63). Complement factors 




polymorphisms or deficiency in early complement components such as C1q and C4 
predisposes to loss of immune tolerance and development of SLE(62). Additionally, 
patients with SLE may show hypocomplementaemia as complement factors, especially C3 
and C4, continue to be sequestered by immune complexes(64).  
Activation of neutrophils by complexed antibodies and complement stimulates formation 
of neutrophil extracellular traps (NETs), fibrous networks containing nuclear and granular 
factors as well as pro-inflammatory proteins and complement factors(65, 66). 
Inflammasome activation and prolonged display of autoantigens strongly links NETs to 
autoimmunity and vasculitis; autoantigens trapped within the NETs can also undergo post-
translational modifications that render them more immunogenic, such as citrullinated 
histones(65). As well as this, reduced DNase activity in SLE impairs NET removal, supporting 
chronic inflammation, particularly when NET clearance is impaired in germinal centres and 
thus exposing autoantigens to autoreactive B cells(65, 66). Indeed, activation of neutrophils 
in SLE induces a shift from immune complex phagocytosis to inflammatory NET 
formation(67), one of a number of suspected impairments in SLE neutrophils. As well NET 
overproduction and reduced degradation, neutrophils of patients with SLE have been 
found to have impaired phagocytosis combined with increased aggregation and production 
of inflammatory mediators(68). In this way, immunogenic material including oxidised 
mitochondrial DNA may be extruded from the neutrophil and proceed to activate further 
leukocytes such as dendritic cells(69). 
The activated dendritic cells then release large amounts of interferon-α (IFNα), which play 
a major role in SLE pathogenesis and as such, will be revisited in later chapters(69, 70). IFNα 
is greatly immunostimulatory, skewing T cell development in favour of Th1 rather than Treg 
pathways, enhancing inflammasomal activity and mobilising BLyS for B cell differentiation 
(70). Dendritic cells activated by autogenic immune complexes also directly promote 
expansion of autoreactive B cells alongside failed induction of regulatory B cell phenotypes 
(71, 72). A similar pattern is present in T cell subsets, in that T cells of patients with SLE 
show a skew in favour of inflammatory Th17 cells and away from Treg cells, thus losing self-




The inflammatory environment of SLE is complex, featuring many interwoven pathways 
that culminate in a cycle of autoreactivity. This chronic inflammation then opens the door 
to tissue damage, resulting in symptomatic disease. 
 
 
1.2.2. Cardiovascular Disease in SLE 
Cardiovascular disease is a leading cause of mortality and morbidity in SLE(75, 76); risk of 
experiencing a major cardiovascular event is significantly higher, up to fifty times in some 
SLE populations(77, 78). Patients with SLE develop subclinical atherosclerosis and plaque 
development that takes an accelerated course compared to a healthy population(79, 80). 
However, endothelial dysfunction is also present in SLE without previous cardiovascular 
history and thus presents an interesting area of study(81, 82). 
There are numerous factors that could explain the increased cardiovascular risk in SLE, and 
the inflammatory environment plays a large role. For example, type 1 interferons such as 
IFNα are associated with endothelial dysfunction and plaque development in murine SLE 
models(83). In vitro studies have found that IFNα produces an endothelial ‘interferon 
signature’ of induced genes comparable to those observed in SLE(84), and suppresses 
production of endothelial NO synthase, promoting endothelial dysfunction(85). Moreover, 
within patient populations, type 1 IFNs correlate with endothelial dysfunction and vascular 
calcification(86). Type 1 interferons may also support increased lipid uptake and foam cell 
formation, furthering atherogenesis(87).  
Other SLE-related cytokines, including B lymphocyte stimulator (BLyS) and TNFα, may 
contribute to atherogenesis. Indeed, patients with genetically high levels of BLyS show 
accelerated plaque formation and arterial wall thickening(88), while elevated levels of 
TNFα have been linked to endothelial dysfunction and premature atherosclerosis in SLE(89, 
90). This is unsurprising as TNFα has already been implicated in atherosclerosis in other 
diseases and models(40, 42, 91). BLyS and TNFα will be used to generate in vitro models of 




On the other hand, IgM antibodies may offer a protective role in SLE, as introduced earlier. 
These antibodies may recognise components of atherosclerotic plaques such as oxidised 
lipids, reducing incidence and risk of cardiovascular events(92, 93). Antibody subtyping 
shows potential for future biomarker development in SLE; IgG antibodies targeting 
cardiolipin, HDL and paraoxonase 1 have already been suggested alongside 
atheroprotective IgM(93-95).  
The cellular aspects of inflammation in SLE additionally contribute to atherogenesis. One 
study found a specific neutrophil subset in patients, which carried an atherogenic gene 
signature and was associated with vascular inflammation as well as atherosclerosis(96). 
Further research described endothelial dysfunction induced by MMPs associated with 
NETs, which would establish chronic subclinical atherogenesis in SLE(97). Similarly, 
monocyte subsets have been linked to subclinical atherosclerosis in SLE(98), alongside 
distinct SLE-specific gene profiles in differentiation of monocytes to macrophages(99).  
Finally, non-traditional risk factors and pathological mechanisms remain to be elucidated. 
Other circulating elements that could contribute to atherosclerosis in SLE include 
transformed, pro-inflammatory HDL, elevated homocysteine and presence of 
adipokines(100). Vitamin D status is another area for further study, as deficiency is linked 
to endothelial dysfunction in both mouse and patient studies(101, 102). Furthermore, 
treatment options for SLE should also be taken into account – corticosteroid use is 
associated with atherosclerosis in SLE, whereas hydroxychloroquine shows 
atheroprotective properties(100, 103, 104). 
 
1.2.3. Improvements are Needed in SLE Diagnostics 
 
1.2.3.1. Diagnosis of SLE 
A diagnosis of SLE may be complicated by the remittent nature of the disease and the high 
variability between patients. The diagnostic criteria published by the American College of 
Rheumatology (ACR; Table 1.1) are among the most common methods used for SLE 
diagnosis with specificity and sensitivity of 95% and 85% respectively, provided the patient 




identified symptoms spanning a variety of organs, as well as the presence of anti-nuclear 
antibodies at a titre of ≥1:160 (106, 107). These criteria were then further developed in 
2012 by the Systemic Lupus International Collaborating Clinics (SLICC) group, producing an 
alternative ‘SLICC’ diagnostic tool, featuring seventeen variables (Table 1.2). This was 
intended to clarify potentially overlapping symptoms such as ‘malar rash’ and 
‘photosensitivity’, further define organ involvement, and increase both specificity and 
sensitivity(106). Both methods may be used in the clinic to ensure definitive diagnosis; the 
current use of two similar techniques highlights the need for a further updated method 





Fixed erythema, flat or raised, over the malar eminences, 
tending to spare the nasolabial folds 
Discoid Rash 
Erythematous raised patches with adherent keratotic scaling 
and follicular plugging; atrophic scarring may occur in older 
lesions 
Photosensitivity Skin rash in response to sun exposure 
Oral Ulcers Painless oral or nasopharyngeal ulceration 
Arthritis 
Nonerosive arthritis of 2 or more peripheral joints, associated 
with tenderness, swelling or effusion 
Serositis Pleuritis or pericarditis 
Renal Disorder 
Persistent proteinuria >0.5g/day or 3+ on dipstick, or cellular 
casts present 
Neurologic Disorder Seizures or psychosis 
Haematologic 
Disorder 
Haemolytic anaemia with reticulocytosis, leukopenia 
<4000/mm3 on ≥2 occasions, lymphopenia <1500/mm3 on ≥2 
occasions or thrombocytopenia <100,000/mm3 in the absence 
of offending drugs 
Immunologic 
Disorder 
Anti-DNA, anti-Sm or positive finding of antiphospholipid 
antibodies based on i) abnormal serum level of IgG or IgM 
antibodies ii) positive test result for lupus anticoagulant or iii) 
false positive serologic test for syphilis known to be positive for 
min. 6 months 
Antinuclear 
Antibody 
Abnormal titre by immunofluorescence or equivalent assay at 
any point in time and in the absence of drugs 
 
Table 1.1: Diagnostic criteria for SLE, as specified by the American College of 
Rheumatology 1997 revised ACR criteria(109, 110). SLE confirmed by positive presence of 





Clinical: Acute Cutaneous Lupus 
Lupus malar rash, bullous lupus, toxic epidermal 
necrolysis variant, maculopapular lupus rash, 
photosensitivity or subacute cutaneous lupus 
Clinical: Chronic Cutaneous Lupus 
Classic discoid rash, hypertrophic lupus, lupus 
panniculitis, mucosal lupus, lupus 
erythematosus tumidus, chilblains lupus, discoid 
lupus/lichen planus overlap 
Clinical: Oral Ulcers 
Palate, buccal, tongue or nasal in the absence of 
other causes 
Clinical: Nonscarring Alopecia Diffuse thinning or hair fragility 
Clinical: Synovitis 
Involvement of ≥2 joints, characterised by 
swelling or effusion, or tenderness and ≥30 
minutes morning stiffness 
Clinical: Serositis Pleuritis or pericarditis 
Clinical: Renal 
Persistent proteinuria >0.5g/day or red blood 
cell casts 
Clinical: Neurologic 
Seizures, psychosis, mononeuritis multiplex, 
myelitis, peripheral/cranial neuropathy or acute 
confusional state 
Clinical: Haemolytic Anaemia 
Haemolytic anaemia with reticulocytosis, 
leukopenia <4000/mm3 on ≥2 occasions, 
lymphopenia <1000/mm3 on ≥2 occasions or 
thrombocytopenia <100,000/mm3 in the 
absence of offending drugs 
Clinical: Leukopenia or 
Lymphopenia 
<4000/mm3 at least once or <1000/mm3 at least 
once 
Clinical: Thrombocytopenia <100,000/mm3 at least once 
Immunological: ANA Above laboratory reference range 
Immunological: Anti-dsDNA 
Above laboratory reference range, or twice 
above if using ELISA 
Immunological: Anti-Sm  
Immunological: Anti-phospholipid 
Antibody 
Lupus anticoagulant, false positive RPR, 
medium-high titre anticardiolipin or anti-β2 
glycoprotein I 
Immunological: Low Complement Low C3, C4 or CH50 
Immunological: Direct Coombs Test In the absence of haemolytic anaemia 
 
Table 1.2: Diagnostic criteria for SLE, as specified by the Systemic Lupus International 
Collaborating Clinics 2012 report(106). SLE confirmed by positive presence of ≥4 criteria, 
including both clinical and immunological or a combination of ANA/ anti-dsDNA antibodies 





Further tools exist to determine patients experiencing a disease flare, thus supporting 
clinical decisions regarding treatment plans. The British Isles Lupus Assessment Group 
(BILAG) is a popular method due to its sensitive and comprehensive review of multiple 
organ systems, and its emphasis on the intention to treat. The system comprises an 
assessment of eight organ systems, with a score assigned to each based on symptomatic 
activity over the previous four weeks. The appearance of a new active or intermediate 
symptom in at least one organ system then indicates flared disease(111-113). Other 
methods include the Systemic Lupus Erythematosus Disease Activity Index, a global 
evaluation of disease activity in nine organ systems over the previous ten days(112). Both 
methods have comparable sensitivity however BILAG is considered most representative of 
disease activity over time(113). 
 
 
1.2.3.2. Diagnosis of Cardiovascular Risk 
 
1.2.3.2.1. Cardiovascular Risk Algorithms are Used Worldwide 
A number of diagnostic tools have been developed for evaluation of cardiovascular risk, 
supporting identification of high risk patients who would benefit from clinical intervention. 
Screening algorithms, such as the Framingham risk calculator, predict cardiovascular risk 
based on factors such as age, blood pressure and cholesterol levels, although age 
consistently produces the dominant effect. Nevertheless, risk estimation appears to vary 
between algorithms(114).  
The Framingham risk score was derived from a large-scale study spanning thousands of 
American citizens and is now a widely used risk tool across the globe. However, it has also 
been considered less representative of varied populations, overestimating risk in multi-
ethnic communities(115, 116). Other algorithms such as Systematic COronary Risk 
Evaluation (SCORE), which stratifies risk groups across Europe, have been considered more 






1.2.3.2.2. The Use of QRISK Algorithms in Cardiovascular Risk Stratification 
In light of the growing cultural diversity in the United Kingdom, a new CVD risk score 
targeted for the modern UK population was developed in 2007. QRISK was shaped using 
health records for approximately 7% of the population, supporting validation of 
cardiovascular risk factors and development of a risk equation using the Cox proportional 
hazards model. This algorithm aimed to provide a more extensive review of risk factors, 
with improved discrimination for a diverse population compared to Framingham(117).  
As knowledge grew, this was further updated in 2008, producing QRISK2, with the inclusion 
of additional risk factors, self-assigned ethnicity and inter-relationships between factors, 
which is updated yearly(118, 119). The QRISK2 algorithm proved superior to the 
Framingham risk score, estimating risk with greater accuracy and avoiding the 
overestimation within the mixed population(120); it is now the CVD risk tool recommended 
by the National Institute for Health and Care Excellence (NICE) for clinical use in the UK, 
with a score of ≥10% indicating high risk(121). 
However, NICE also recognised the increased cardiovascular risk in SLE and associated 
medications, such as corticosteroids, advising that risk may be underestimated in this 
population(122). Risk underestimation in patients was also observed when using 
Framingham, indicating the need for an SLE-inclusive score(123), such as that suggested by 
Fava et al.(124) and will be an area of investigation in this study.  
 
 
1.2.3.2.3. Identification of Cardiovascular Risk in SLE 
In 2017, an updated QRISK3 algorithm was produced to address the issues of inclusivity. It 
did this by incorporating a number of additional risk factors, including both SLE and 
corticosteroid prescription (Table 1.3). As with previous algorithms, a 10% likelihood of 
experiencing a major cardiovascular event over the proceeding 10 year period was deemed 
‘high risk’.  
When Hippisley-Cox et al. validated and compared this to QRISK2, they found an 




independently evaluated, particularly within a cohort of patients with SLE. Our interest in 
developing the QRISK3 algorithm extends to a current biomarker of interest, namely 
endothelial microvesicles, which show promise as a marker of endothelial damage.  
Accurate identification of patients with high cardiovascular risk would enable early 
provision of treatment and monitoring, potentially preventing premature mortality and 





Age (30-79 years) Age (25-84 years) Age (25-84 years) 
Sex Sex Sex 
Smoking status Ethnicity Ethnicity 
Total cholesterol UK postcode UK postcode 
HDL cholesterol Smoking status Smoking status 
Systolic blood pressure Diabetes status Diabetes status 
Blood pressure 
medication 
Angina or heart attack in a 
1st degree relative <60 
Angina or heart attack in a 1st 
degree relative <60 
 Chronic kidney disease 
(stage 4-5) 
Chronic kidney disease (stage 
3-5) 
 Atrial fibrillation Atrial fibrillation 
 Blood pressure medication Blood pressure medication 
 Rheumatoid arthritis Migraines 
 Cholesterol/HDL ratio Rheumatoid arthritis 
 Systolic blood pressure Systemic Lupus 
Erythematosus 
 Body mass index (height, 
weight) 
Severe mental illness 
  Atypical antipsychotic 
medication 
  Regular steroid medication 
  Erectile dysfunction 
  Cholesterol/HDL ratio 
  Systolic blood pressure 
  Standard deviation of min. 2 
most recent systolic blood 
pressure readings (mmHg 






Table 1.3: A comparison of cardiovascular risk algorithms available in the UK. The 
updated QRISK3 algorithm includes novel risk factors relevant to patients with SLE, such as 
SLE and steroid medication. Additional risk factors highlighted in bold. Severe mental illness 
is inclusive of schizophrenia, bipolar disorder and moderate-severe depression. 
 
 
1.3. Endothelial Microvesicles as Biomarkers and Effectors of Endothelial 
Dysfunction 
 
1.3.1. Endothelial Microvesicles 
Endothelial microvesicles (EMVs) are anucleoid, membrane-bound cell fragments 100-
1000nm in size, characterised by a phospholipid bilayer studded with phosphatidylserine 
(PS). EMVs are released in response to diverse stimuli, including shear and oxidative stress, 
and have been found to transport bioactive proteins, lipids, mRNAs and microRNAs 
(miRNAs) to recipient cells. In this way, they have been considered as future biomarkers, 
as well as effectors of disease and repair processes (125-127).  
 
 
1.3.1.1. Identification of EMVs 
The presence of extracellular vesicles (ECVs) in plasma and blood products was first 
communicated by Peter Wolf in 1967, who referred to them as ‘platelet dust’(128). Since 
then, ECVs have been scrutinised and found to be quite the opposite of the ‘cell debris’ 
they were first thought of; ECVs have been shown to mediate endocrine and paracrine 
effects(125, 127). ECVs were subsequently classified according to size and cellular origin. 
Current understanding is that there are three distinct groups of vesicles present in the 
extracellular space, with specific characteristics and mechanisms of formation. Of these, 
microvesicles are defined by their size, release pathway and unique surface markers 
obtained from the membrane of the donor cell, which can be determined using labelled 




between the varied microvesicle populations present in blood, such as those of endothelial 
origin (EMVs) compared to platelet-derived microvesicles (PMVs)(126, 129).Nomenclature 




Figure 1.4: The characteristics and phenotypic distinctions of EMVs. Endothelial 
microvesicles are characterised by a number of phenotypic features including specific 
surface markers representative of the endothelial lineage, which are often upregulated 
following cell activation e.g. ICAM-1, CD144, CD31. These can be detected using labelled 
antibodies; the presence of phosphatidylserine (PS) within the membrane can also be 
detected by labelling annexin V. Adapted from Yin et al. (2015). 
 
 
1.3.1.2. EMV Release and Uptake 
EMVs are released by blebbing from the cell membrane following cellular activation, a 
process that occurs seconds after activation and cytoskeletal disruption(130). This results 
in downstream calcium signalling and ROCK1 activation, which leads to translocation of 
phosphatidylserine, a cytoplasmic aminophospholipid, to the cell membrane(125). 




extracellular vesicles, although transfer of contents can also be enabled by receptor-
mediated, clathrin-independent endocytosis and pinocytosis(126, 131-133). Despite this, 
microvesicular uptake appears dependent on a number of variables such as membrane 
composition, and both intracellular and extracellular conditions. Donor and target cells can 
also be of different lineages (Figure 1.5)(133, 134). 
The first evidence of this uptake was presented by Scholz et al. in 2002(135) whereas the 
first evidence of miRNA transfer, albeit in exosomes, was published by Valadi et al. in 2007 
followed by microvesicular miRNA transfer by Yuan et al. in 2009(136, 137). The possibility 
of transfer of material using MVs provides new therapeutic options and potential for 
delivery of drugs(126, 127, 129, 133). Once released, MVs are cleared fairly rapidly, most 
likely by hepatic or phagocytic mechanisms; monocellular culture means they are quite 




Figure 1.5: Proposed mechanisms of EMV uptake. Uptake appears to be dependent on the 
environment and interacting cells, with potential mechanisms including A: membrane 
fusion, B: ligand-receptor interactions, C: extracellular degradation, D: caveolin-dependent 
endocytosis, E: phagocytosis and F: micropinocytosis. EMVs are referred to here as EMPs 




1.3.2. EMV Content: miRNA 
As described previously, EMVs transport bioactive contents through the circulation, and 
can transfer these to recipient cells(125). EMV contents include miRNAs, which offer 
potential for further cardiovascular biomarker studies and patient stratification(139), as 




1.3.2.1. MiRNA Structure and Function 
Small RNAs are found across eukaryotic organisms and are defined by a size of 20-30 
nucleotides. Of this family, miRNAs are a dominant class, comprising 18-22 
nucleotides(140, 141).  
Transcription of miRNA genes by RNA polymerase II results in a long transcript with miRNA 
sequences found within a hairpin structure; the initial products are primary miRs (pri-miRs), 
which are then processed into pre-miRs by RNAse III protein Drosha prior to nuclear export. 
Once within the cytoplasm, another RNAse III protein, Dicer, further processes the pre-
miRs into mature and functional miRNA. In most cases, these miRNAs proceed to bind to 
3’UTR sites of target mRNA and regulate their expression (figure 1.6)(140, 141). They do 
this by two modes of action; miRNAs can integrate into a ribonucleoprotein RNA-induced 
silencing complex (RISC) which then either silences gene expression by e.g. endonucleolytic 
cleavage of mRNA or blocks translation through recruitment of repressors(142). 
The miRNA gene family is extremely abundant and as such, has complex nomenclature and 
relationships. It is relatively common to find similar miRNA loci that are products of gene 
duplication, and therefore mature miRNAs with identical sequences within the first 2-7 
nucleotides (the miRNA ‘seed’) are considered part of the same family. miRNAs can also 
share a common origin and so belong to an evolutionary superfamily but demonstrate 
single nucleotide differences within the miRNA seed sequence. Nomenclature may also be 
inconsistent, with miRNAs referred to according to phenotype, e.g. let-7, or numerically by 




b, while the directionality of the miRNA transcription from the loci is also described e.g. 
miR-30d-5p(140, 143).  
 
 
Figure 1.6: MiRNA formation and action in relation to mRNA. miRNAs are processed in the 
nucleus before final cleavage in the cytoplasm, producing mature miRNA. Once mature, the 





1.3.2.2. MiRNAs in CVD 
Disease-specific miRNAs show great promise for both mechanistic and biomarker studies. 
As yet, a clear picture of the role of miRNAs in cardiovascular health has not been 
determined however numerous studies have suggested roles for individual miRNAs 
associated with various cardiovascular morbidities. The sheer quantity of identified human 
miRNAs makes a full description of their potential actions beyond the scope of this work, 
although summaries of possible cardiovascular interactions have been elegantly reviewed 
elsewhere(141, 144).  
As mentioned, miRNAs can post-transcriptionally alter gene expression, most commonly 
preventing translation of target mRNAs. The mRNA targets differ between miRNAs; one of 
the most extensively studied miRNAs in cardiovascular research is miR-145, which appears 
to be pro-atherosclerotic, through phenotypic switching and fate determination of VSMCs 
(145-147). MiR-21 also acts on VSMCs, and by doing so can influence the stability of 
atherosclerotic plaques, but has historically been studied for its role in fibrosis and cardiac 
function(144, 148, 149). In this way, miRNAs can have unique roles that interrelate and 
create a dynamic environment during vascular health and disease. 
The associations between certain miRNAs and disease states supports the development of 
miRNA ‘signatures’ as biomarkers of disease activity. For example, miR-126-3p (and miR-
145-3p) has been recommended as a biomarker of acute myocardial infarction(150), while 
miR-93 has been suggested for use in stroke diagnosis, as well as coronary artery 
disease(151, 152). Thus the quantification of individual miRNAs packaged into EMVs shows 
great potential in the fields of diagnostics and precision medicine(153) and will be 
investigated in this study within the context of SLE.  
 
 
1.3.3. EMVs as Biomarkers of Cardiovascular Risk  
By providing a ‘snapshot’ of valuable information regarding the state of the endothelium, 
EMVs have been suggested for future use as biomarkers in cardiovascular disease. Indeed, 




coronary endothelial dysfunction and increased risk of a major cardiovascular event (125, 
154-156).  
EMVs and their contents may also be utilised in other conditions, such as SLE. Our group 
has previously shown that circulating EMVs are elevated in patients with SLE compared to 
controls, and not only were associated with endothelial dysfunction, but also could be 
reduced by immunosuppressive therapy, implying a connection between EMVs and 
inflammation(157-159). Suggested effects of microvesicles in SLE include stimulation of 
NETosis, immune complex formation and ROS production(160-163); a number of studies 
have also performed high throughput screening of miRNAs isolated from blood, although 
the primary focus is often on lupus nephritis or mononuclear cells(164-167). Characterising 
EMV function in SLE within the context of cardiovascular involvement is a relatively novel 
area; and should provide crucial knowledge to the field of diagnostics and treatment of SLE 
through innovative biomarker development and identification of future targets for therapy. 
 
 
1.4. Hypothesis, Aims and Objectives 
 
1.4.1. Study Summary and Rationale 
Incidence of cardiovascular disease is increased in SLE, meaning young patients are at risk 
of endothelial damage, subclinical atherosclerosis and premature death. It is therefore 
critical that this risk is recognised.  
1.4.2. Hypothesis 
We hypothesise that endothelial damage may be assessed through the identity and 
quantification of EMVs as novel biomarkers, and in vitro models using endothelial cells may 
be used to interrogate the mechanisms by which the endothelium becomes damaged in 
SLE. 
The overarching aim of this study is to establish whether EMVs can be added to the 





1.4.3. Aims and Objectives 
The specific aims and objectives of this project are thus: 
AIM 1: To identify novel biomarkers for cardiovascular risk in SLE.  
 Objective 1. Clinical cardiovascular risk algorithms will be compared in relation to 
markers of inflammation and cardiovascular health in a cohort of patients with SLE 
using SPSS statistical software. 
 Objective 2. EMV levels in the SLE cohort will be quantified using flow cytometry to 
establish whether correlations might exist with clinical data. 
 
AIM 2: To determine a vesicular miRNA signature in patient plasma. 
 Objective 1. Data mining will be used to screen miRNAs of interest, which will be 
quantified in patient plasma by quantitative PCR and correlated with clinical data. 
 Objective 2. Predicted miRNA targets will be identified by gene ontology analysis. 
 
AIM 3: To elucidate functional effects of SLE-related miRNAs in endothelial cells. 
 Objective 1. An in vitro model of miRNA overexpression will be generated using a 
lentiviral vector transfer strategy. 
 Objective 2. The effects of miRNA overexpression on endothelial cell function will 













Materials and Methods 
 
 
2.1 . Mammalian Cell Culture 
Cell culture plates, flasks and plasticware were obtained from ThermoFisher Scientific. To 
ensure sterility, cells were handled within a class II safety cabinet and relevant equipment 
treated with 70% v/v industrial methylated spirits (Fisher).  
 
 
2.1.1. Culture and Passage of Human Umbilical Vein Endothelial Cells (HUVECs) 
Early passage HUVECs from pooled donors were sourced from Caltag Medsystems and 
revived in complete endothelial cell growth medium MV2, with supplied supplements 
(Promocell) and 1% v/v penicillin/streptomycin mix at 10,000U/ml each (Lonza).  
0.1% w/v bovine skin gelatine (Sigma) diluted in phosphate-buffered saline without Ca2+ or 
Mg2+ (PBS; Lonza) was used to coat culture vessels by incubating for 30 minutes prior to 
removal and washing with PBS. Individual vials of cells were seeded into 25cm2 flasks, 
where they were incubated at 37°C, 5% CO2 until confluence and for routine maintenance, 
passaged 1:3 into 75cm2 flasks, twice weekly using 200mg/L trypsin (Lonza) as a 
dissociation reagent (2ml per 25cm2). Cells were cryopreserved in 10% dimethyl sulphoxide 
(DMSO; Sigma), 40% foetal calf serum (FCS), 50% media and chilled for 24 hours in a 
Nalgene® Mr Frosty freezing container at -80°C prior to storage in liquid nitrogen. To enable 
revival, cryopreserved cells were thawed at 37°C for <5 minutes before seeding into pre-
warmed media (25cm2). Media was discarded and fresh added at 24 hours, to ensure 





2.1.2. Culture and Passage of Human Embryonic Kidney 293T Cells  
HEK293T cells (ATCC® CRL-3216™)  at early passage were revived and cultured in Dulbecco’s 
Modified Eagle’s Media (DMEM; Lonza) with supplementation as specified below. Revived 
cells were transferred directly to 75cm2 flasks and incubated as in 2.1.1. Cells were 
passaged once confluent (2-3 times weekly), at a ratio of 1:6 using 200mg/L trypsin as 
before, and cryopreserved as in 2.1.1. 
DMEM Media Composition 
DMEM (Lonza) 
10% FCS (ThermoFisher Scientific) 
1% L-glutamine (Corning) 
1% Penicillin/streptomycin mix (Lonza) 
 
 
2.2. Cellular Function Tests 
 
2.2.1. Cell Treatment: Cytokines 
10ng/ml TNFα and BLyS (Peprotech) were used to treat cells and simulate the inflammatory 
environment present in patients with SLE, as these cytokines are commonly associated with 
the disease, as discussed in chapter 1. 
 
 
2.2.2. Cell Viability: Alamar Blue Assay 
 
Cells were cultured in clear 96 well microplates at 1x104 cells per well in 100μl media. 10ul 
alamarBlue reagent (Invitrogen) was added and plates incubated for 24 hours. Absorbance 
was then read at 570/600 and fluorescence at 530/590 using a Synergy™ HT Microplate 






2.2.3. Scratch Migration Assay 
 
Cells were plated at 1x105 cells per well and cultured to confluence in 12 well culture plates. 
A P200 pipette tip was used to draw a vertical line through each well, creating a cell-free 
scratch area. Media was then removed and cells washed with PBS twice to remove non-
adherent cells. Media was replaced and images were taken at x4 magnification on a Zeiss 
Primovert inverted microscope with Axiocam 105 colour camera at 0, 5 and 24 hours. 
Images were then analysed using ImageJ software. 
 
 
2.2.4. Angiogenic Tube Formation Assay 
 
Prior to performing this assay, Matrigel® Matrix (Corning) was refrigerated on ice overnight 
to thaw slowly, alongside pipette tips and a clear 96 well microplate. On the day of the 
assay, 30μl of Matrigel® was used to coat the microplate wells, which were then incubated 
for 30 minutes at 37°C in order to set. Next, cells were plated on top of the matrix at 9x103 
per well in 50μl media. Images were taken at x10 magnification using the Zeiss microscope 
at 5 and 24 hours. Images were analysed manually, using ImageJ software and the 









Figure 2.1: Flowchart for tube recognition in manual angiogenesis analysis. 
 
 
2.2.5. Seahorse Mitochondrial Bioanalysis 
 
Seahorse bioanalysis allows interrogation of oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR), providing data on mitochondrial and glycolytic 
respiration. To do this, compounds are sequentially added to cells, which inhibit or boost 
certain respiratory pathways. In this work, oligomycin, carbonyl cyanide-4-
phenylhydrazone (FCCP) and rotenone/antimycin A were injected to target the respiratory 







Figure 2.2. Seahorse cell mito stress test profile. When performing a cell mito stress test, 
oligomycin is injected first to inhibit ATP synthase, reducing mitochondrial respiratory 
ability. FCCP is next added to disrupt the proton gradient and alter mitochondrial membrane 
potential, increasing OCR to maximum. The final addition is a mix of rotenone and antimycin 
A, which inhibit complexes i and iii of the mitochondrial electron transport chain, stopping 
all mitochondrial respiration. Figure courtesy of Agilent Technologies. 
 
Cells were plated at 8x103 cells per well into a Seahorse XF96 Cell Culture Microplate and 
cultured overnight under standard conditions (section 2.1.1). On the day of the assay, a 
Seahorse XFe96 FluxPak was hydrated in Seahorse XF calibrant solution for 1 hour and cell 
media was changed to Seahorse XF base media supplemented with 1mM pyruvate, 2mM 
glutamine and 10mM glucose (all Sigma) at pH 7.4 for 45-60 minutes. Mitochondrial 
function was then assessed using a Seahorse XFp Cell Mito Stress Test kit, in accordance 
with kit protocol. Seahorse reagents were acquired from Agilent Technologies. Consistent 




2.3 .  EMV Isolation and Quantification 
 
2.3.1. EMV Isolation 
 
Whole blood samples were centrifuged at 1,500g for 10 minutes at 4°C and the plasma 
removed. Plasma was then centrifuged at 20,000g for 10 minutes at 4°C and the 
supernatant harvested, and stored at -80°C prior to analysis by flow cytometry or use in 
experiments. When isolating EMVs released from cells in culture, the media was removed 
and centrifuged at 1,500g for 10 minutes at 4°C. The supernatant was harvested and stored 
as above. 
Exosome-free media was prepared using media with 2% exosome-depleted FCS. The FCS 
was prepared by ultracentrifugation at 100,000g for 18 hours using an OptimaTM XE 
ultracentrifuge (Beckman Coulter). The exosome-rich pellet was discarded and supernatant 
used in the media. 
 
 
2.3.2. EMV quantification 
Optimisation of settings on FACSVerse (BD) was undertaken prior to flow cytometric 
analysis. Polystyrene beads of known size (Spherotech) were used to identify and gate 







Figure 2.3:  Vesicle positioning using beads of known size. A and B: The use of 
phycoerythrin (PE)-labelled beads allows identification of the areas in which MVs would 








Figure 2.4: Establishment of gates to characterise MV populations. MVs isolated from 
exosome-free media following cell treatment with TNFα exhibited a characteristic tail 
appearance under flow cytometry (A), compared to fresh exosome-free media (C). There 
was also high particulate density in regions corresponding to larger vesicle size (D), which 
was not present in media only (B). Gating was conducted to maximise capture of tail areas 










Flow cytometry was then performed to quantify MV numbers present in human plasma 
and to characterise their cellular origin, such that EMVs may be identified. Patient plasma 
was isolated as described in 2.3.1 and 20µl added to a flow tube. Tube contents were made 
up to 200µl with 1µl each of CD31 antibody labelled with BD Horizon Brilliant™ Blue 515, 
CD144 and CD42b antibodies, 5µl count beads (Beckman Coulter; Table 2.1) and 172µl 
0.22µm-filtered PBS. Following this, tubes were kept on ice in the dark for 30 minutes 
before flow cytometric analysis. 
 
Antibody Company 
BB515 Mouse Anti-Human 
CD31 
BD Biosciences 
PE Mouse anti-Human 
CD144 
BD Biosciences 









2.4 . MiRNA Analysis 
 
2.4.1. MiRNA Selection 
A literature search of PubMed and Google Scholar was performed on publications up to 
October 2017 using keywords ‘miR’ and ‘SLE’, ‘systemic lupus erythematosus’, 
‘cardiovascular’, ‘endothelial’, ‘microvesicles’, ‘microparticles’ or ‘extracellular vesicles’. 
Results of miRNA sequencing, microarray and qPCR analysis of adult cell-free plasma and 
EMVs were noted, whilst experiments using other cell types, such as lymphocytes and renal 
cells, were excluded. Only primary research papers were used; review articles were utilised 
solely as reference guides.  
A shortlist of potential miRNAs of interest was produced based on extent of current 
knowledge, notes found in relevant papers, unpublished preliminary data previously 




from DAVID(169, 170) and TargetScan(171) regarding potential implicated molecular 
pathways. 7 miRNAs of interest were chosen based on this method and located across 14 
research papers; let-7a was also included for analysis as a ‘housekeeper’, as it has often 
been suggested by other researchers, albeit in oncogenic settings, and is frequently 
reported in numerous tissue types, including endothelial cells, in publication and on 
ExoCarta/Vesiclepedia miRNA databases(172-176). 
 
 
2.4.2. MiRNA Isolation and Amplification 
 
Prior to miRNA isolation, plasma and media samples, which had previously been processed 
as in 2.3.1., were centrifuged at 100,000xg for 1 hour at 4°C to extract the vesicular fraction.  
MiRNA was isolated using a miRNeasy micro kit (Qiagen), from 1ml plasma or following kit 
instructions regarding starting amount of cellular material. To amplify transcripts for 
quantification, reverse transcription was performed using miRCURY LNA reverse 
transcription kit (Qiagen) following the manufacturer’s instructions. Incubation cycles were 
performed on an Agilent Sure Cycler 8800 Thermocycler, as below, and cDNA stored at -
20°C. 
Incubation Protocol 
42°C – 60 mins 
95°C – 5 mins 




2.4.3. MiRNA Quantification 
 
MiRNA abundance was analysed by qPCR using the cDNA generated as in 2.4.2. This was 
achieved using miRCURY LNA miRNA PCR assays (Qiagen) with primer sequences below 














Table 2.2: LNA miRNA PCR assay primers used in quantification of miRNAs. 
 
 
Kit instructions were followed, using the 60x dilution for plasma and cellular analysis, and 
10x dilution for vesicles generated in vitro. 7μl mastermix (composition below) was added 
to wells of a 0.2ml semi-skirted 96-well plate (Starlab) before inclusion of 3μl cDNA in each 
well. A qPCR reaction was then performed in a 2-step program on an Applied Biosystems 
Step One Plus Real Time Thermocycler using the protocol below.  
 
Mastermix composition (per well)                                 
5µl 2x miRCURY SYBR green master mix (Qiagen)             
1µl PCR primer mix 
1µl RNase-free water 
 
Cycling protocol 
95°C – 2 mins 
95°C – 10 secs 










2.4.4. MiRNA Predicted Target Identification 
Predicted targets of the miRNAs of interest were recorded from DIANA microT v5(177) and 
matched with results obtained from the Gene Ontology (GO) Consortium(178, 179) 
regarding genes implicated in ‘endothelial cell activation’, ‘blood microparticles’, ‘IFNα 
signalling’, ‘SLE’, ‘cellular respiration’,  ‘ossification’ and ‘bone mineralisation’. 
Cytoscape(180) was then used to identify crucial proteins and pathways targeted, 
highlighting key nodes associated with each miRNA. Finally, the data were ranked according 
to DIANA miTG prediction score and Cytoscape degree ranking.  
 
 
2.5. DNA and Analysis using Electrophoresis  
 
Agarose gels were made to appropriate concentration e.g. 1.5% by diluting ultra-pure 
agarose (Invitrogen) in 1xTBE buffer (ThermoFisher Scientific), boiling to dissolve crystals, 
then addition of Midori green at 0.01% (5μl in 50ml [Nippon Genetics Europe]). The solution 
was poured into a gel cast system with the addition of a comb to form the wells and was 
left to set for 30 minutes at room temperature. 5μl NEB loading dye was added to samples 
prior to loading into the gel, alongside 10μl of 1kb ladder (New England Biolabs) and 
electrophoresis was conducted at 120V for 30 minutes.  
 
 
2.6. Generation of In Vitro MiRNA Overexpression Models 
 
2.6.1. General Bacterial Methods 
 
2.6.1.1. Preparation of Bacterial Broth and Agar 
Lennox Lysogeny Broth (LB) broth and agar mixes (both Sigma) were prepared in deionised 
water, in accordance with the manufacturer’s protocol. Both were autoclaved for 15 




was poured over a flame into petri dishes. Antibiotic was mixed into aliquots of bacterial 
broth immediately before use. 
 
 
2.6.1.2.   Preparation of Antibiotics 
100mg/ml stock solutions of kanamycin and ampicillin (both Sigma) were aseptically 
prepared in deionised water, within a laminar flow cabinet. Final working concentrations 
of 50μg/ml and 100 μg/ml were used for kanamycin and ampicillin respectively. Antibiotics 
were stored at -20°C. 
 
 
2.6.1.3.  Preparation of Glycerol Stocks 
Following overnight culture of bacterial colonies in 5ml LB broth, 1ml of culture was 
removed and mixed with 1ml glycerol (Fisher Scientific). Glycerol stocks were then stored 
in cryovials at -80°C.  
 
 
2.6.1.4.  Bacterial Strains and Transformation 
DH5α competent E.Coli cells were used to generate entry clones whereas One Shot™ 
Stbl3™ competent E.coli cells (both Invitrogen) were used in the generation of expression 
clones prior to lentivirus production. To transform cells, 1µl DNA was added to individual 
vials of bacterial cells, which were then chilled for 30 minutes on ice. Next, they received a 
heat shock for 45 seconds at 42°C, followed by a further incubation on ice for 2 minutes. 
Finally, 450µl of room temperature (RT) super optimal broth (SOC media) was added and 





2.6.2. Generation of MiRNA Overexpression Plasmid Constructs by Gateway® Cloning 
Gateway® Cloning technology was first developed by Invitrogen to simplify cloning 
workflows by minimising the use of restriction enzymes and subcloning, while maintaining 
high recombination efficiency(181). Precise recombination is mediated by the inclusion of 
att sites, which only recognise specific enzymes and recombine with their paired att site; 
in this way, nucleotides are neither gained nor lost and DNA can only be inserted 
monodirectionally (figure 2.5). The inclusion of Gateway cassettes containing antibiotic 
resistance and the toxic ccdB gene allow further confirmation of correct 







Figure 2.5: Gateway® Cloning workflow. During step 1, the attB-flanked gene or PCR 
product is combined with a donor vector containing the toxic ccdB gene and expressing 
kanamycin resistance, using BP clonase enzyme. This yields a recombined entry clone with 
the DNA flanked by attL sites and a by-product that is toxic to cells. The entry clone is then 
recombined with a destination vector expressing ampicillin resistance using LR clonase. The 






2.6.2.1.  Design of MiRNA Constructs 
MiRNA sequences were identified using the online National Centre for Biotechnology 
(NCBI) database. Constructs were supplied by Life Technologies, and were designed to 
include flanking sequences for attB1 and attB2, as well as for restriction enzymes Hpa1 and 





Figure 2.6: Representative DNA gel of miRNA constructs. Prior to cloning, purchased 
miRNA constructs were analysed by gel electrophoresis on a 1.5% agarose gel, conducted 
at 120V for 30 minutes. Constructs were digested with restriction enzyme Hpa and Xho1, 
yielding bands at 400-500bp, corresponding with the designed construct, and remaining 
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C T C G G G G G T C T T G G C C T C C G G G C G G T G G C G T G G A G 
G C G C C A A G A T C A G G G T C C C G G G T T T T G T C G G C C A C C 
T C G A G G  
hsa-miR-30d T C T A T T G T T C A G C A C T A G A A A T T A T A T A A A T T A T T A G 
C T G A A G A T G A T G A C T G G C A A C A T T T A T G T C T G T T C C 
T C C T C T T A A A T T T C T T G T T C A G A A A G T C T G T T G T T G T 
A A A C A T C C C C G A C T G G A A G C T G T A A G A C A C A G C T A A 
G C T T T C A G T C A G A T G T T T G C T G C T A C C G G C T A T T C A C 
A G A C A T C C T C T T G A T A T A A T T C T G T C C C G G A G T G G A 
G T T G A G G A G G C T A T A A A A T G T G T G G G A A A A C C T C A G 
A A A T C T T T A G C T G C A T T C T C G A G G  
attB1 C A A G T T T G T A C A A A A A A G C A G G C T 
attB2 A C C C A G C T T T C T T G T A C A A A G T G G T 
Hpa1 G T T A A C 
Xho1 C T C G A G 




2.6.2.2.  Generation of Entry Clones 
The amounts of DNA construct and plasmid pDONR221 (Invitrogen; figure 2.7) to be used 
were calculated using the equation (50 x no. base pairs) x 600 x (1/10^6) = ng. 10ng/μl 
miRNA construct was added to 150ng/μl pDONR221 vector and TE buffer (ThermoFisher 
Scientific), pH 8.0 used to yield an 8μl mixture. BP Clonase II enzyme (Invitrogen) was briefly 
thawed and vortexed, before 2μl was incorporated into the mixture. The reactions were 
then incubated at 25°C for 18 hours. Following this, 1μl proteinase K (Sigma) was added to 
terminate the reactions, which were incubated for 10 minutes at 37°C. 1μl of the BP 
recombination reactions were then used to transform DH5α competent E.Coli cells as 
described in 2.6.1.4. 20μl and 100μl aliquots were plated onto pre-warmed selective plates 




Figure 2.7: Sequence map of pDONR221 vector. Note the presence of attP sites and 
associated restriction enzyme sites. Other restriction enzyme sites have been hidden in 




Individual colonies were subsequently selected and cultured in LB broth with kanamycin, 
overnight at 37°C on a shaker at 200rpm. Following this, entry clone DNA was extracted 
from 4ml of liquid culture using a QiaPrep Spin Miniprep kit (Qiagen) and quantified by 
NanoDrop. Glycerol stocks were generated from the remaining 1ml. To confirm DNA 
integrity of entry clones, 800ng DNA was diluted to 25μl in dH2O. 3μl Cutsmart buffer and 
1μl each Hpa1 and ECORV restriction enzymes (all New England Biolabs) were added, and 
the solution was incubated for 2 hours at 37°C. Gel electrophoresis was then performed 
using a 1% agarose gel, as described 2.5. To improve band visualisation, gels were 
incubated in 1xTAE buffer containing SYBR™ Gold (Invitrogen) at 0.1μl/ml for 15-30 
minutes before viewing under an LED transilluminator (Biorad).  
 
 
2.6.2.3.  Generation of Expression Clones 
Upon confirmation of correct bands, 50-150ng entry clones were added to 150ng/μl 
destination vector, a pLL3.7 lentiviral backbone (Addgene), and TE buffer pH 8.0 used to 
achieve an 8μl solution. LR clonase II enzyme (Invitrogen) was thawed as recommended by 
the manufacturer and 2μl added to each sample before incubation for 18 hours at 25°C. As 
before, the reaction was terminated with 1μl proteinase K and an incubation for 10 minutes 
at 37°C. The same transformation protocol was used to transform One Shot™ Stbl3™ 
competent E.coli cells, which were plated on pre-warmed selective agar plates with 
incorporated ampicillin. Colonies were selected and cultured, DNA extracted as before and 
further glycerol stocks were made. Expression clones (Figure 2.8) were digested using 1μl 
each HPa1 and Xho1 (NEB), and correct banding was checked by gel electrophoresis before 
confirmation by sequencing, described in 2.6.2.4. PLL3.7 plasmids without miRNA 









Figure 2.8: Plasmid maps for pLL3.7 vector and miR-3148 expression clone. Image A 
depicts the pLL3.7 vector utilised in the LR reaction of Gateway® cloning and in control 
lentiviral vectors whereas image B shows the expression clone generated by the 
recombination of pLL3.7 and the miR-3148 construct. Note the inclusion of GFP in the vector 
to mediate fluorescence, and the attB sites flanking the construct. 
 
 
2.6.2.4.  Sequencing of Expression Clones 
Expression clones were prepared for sequencing by adding 1μl of 4pm/μl mU6 primer 
(Addgene) to 300ng DNA in a 10μl H20 solution. The primer sequence was as follows: 
5’AGGAAACTCACCCTAACTGTAAAG. 
Sequencing was performed at the Manchester Regenerative Medicine Network, University 
of Manchester. Thanks to Dr Fraser Combe for coordinating this collaboration. 
 
 
2.6.3.  Generation and Use of Lentiviral Vectors to Transduce Endothelial Cells 
Three plasmids were used to generate virions prior to HUVEC transduction: the pMD.G2 
plasmid (Addgene) encoded the vesicular stomatitis virus glycoprotein (VSV-G) envelope, 
the pCMV--dR8.91 plasmid encoded the human immunodeficiency virus gag/pol/rev genes 
and the previously generated expression clone contained the miRNA overexpression 
construct. The two former plasmids enabled the packaging of the expression clone into 
lentiviral particles (figure 2.9). The pCMV--dR8.91 plasmid was kindly donated by Prof. 







Figure 2.9: Generation and packaging of lentiviral particles. HEK293T cells are transfected 
with plasmids encoding viral envelope and assembly proteins alongside expression clones. 
Assembly of viral proteins is completed in the cytosol, before virions are released, containing 











2.6.3.1.  Generation of Lentiviral Vectors 
7500ng expression clone DNA was added to 5000ng pMD2.G and 10,000ng PCMV plasmids, 
before 150mM NaCl (Fisher) was incorporated to yield a 1ml solution. 7mM 
Polyethylenimine (PEI) reagent (Polysciences) was prepared by diluting PEI stock in 150mM 
NaCl and incubated for 10 minutes at RT. DNA-PEI complexes were then generated by 
adding the PEI reagent to DNA in a dropwise manner, followed by gentle mixing and 
another incubation for 10 minutes at RT. Finally, the resulting mixture was added dropwise 
to HEK293T cells, which had been seeded previously into 6 well plates and cultured to 60-
70% confluency. Media was discarded and replaced after 4 hours and again at 24 hours. 
Virions in cell-free supernatant were harvested at 48 and 72 hours by centrifugation at 
1000g for 10 minutes at 4°C, and aliquots were stored at -80°C.  
 
 
2.6.3.2.   Transduction using Lentivirus 
Lentiviral aliquots were thawed on ice prior to filtration through a 0.22μm filter. In order 
to ascertain viral volume required for efficient transduction, a series of volumes were 
added dropwise to HUVECs at 60-70% confluency. Media was replaced at 4 hours and green 
fluorescent protein (GFP) expression analysed at 48 hours using a Leica CTR 6000 live cell 
imaging microscope at x10 magnification. Comparison of the number of GFP-expressing 
cells compared to non-expressors was performed using ImageJ, and the production of a 
GFP expression gradient indicated that 500μl should be used for each well of a 6 well plate 
in order to obtain 80% transduction efficiency (figure 2.10). For further experiments, 
HUVECs were transduced at passage 3 and GFP expression was tested and confirmed up to 








Figure 2.10: Transduction efficiency of miR-3148 construct. HUVECs at p4 were transduced 
with differing concentrations of lentiviral vectors containing miR-3148 overexpression 
constructs. Images were taken after 48 hours and the ratio of cells expressing GFP was 
calculated manually, producing a titration curve that indicated 500μl lentivirus yielded 
80.6% efficiency. This was repeated with 5 other miRNA constructs. Experiments were 
performed in triplicate, with error bars denoting SEM. Scale bar=200μm. 
 
 
2.6.3.3. Confirmation of MiRNA Overexpression by QPCR 
Following transduction of HUVECs with lentiviral vectors, intracellular abundance of miRNA 
was quantified to confirm successful upregulation of each miRNA (figure 2.11). 
Transduction with miR-126-3p, miR-320a and miR-30d-5p constructs increased abundance 
2 – 4.5-fold compared to HUVECs transduced with the empty pLL3.7 plasmid. Transduction 




large error bars ranging from 4-23-fold; the n=2 prevents determination of whether this is 
a true finding or if the larger value was the result of an error. Only miR-3148 abundance 
did not change following transduction, which may be due to the low abundance and 




Figure 2.11: MiRNA abundance following transduction with lentiviral vectors. HUVECs 
were transduced with 500μl of miRNA-containing lentiviral vectors at passage 3, and 
cultured to passage 4 before miRNA was extracted. Abundance of key miRNAs were 
quantified by qPCR to confirm successful overexpression. Data shown represent abundance 
following transduction relative to control cells transduced with empty pLL3.7 plasmid. Error 










2.7.   Patient Studies 
Controls and patients with SLE were identified and recruited by clinical collaborators at the 
Kellgren Centre for Rheumatology, Manchester Royal Infirmary. Patients were identified 
according to the 1997 ACR criteria(109), with exclusion criteria consisting of current 
infection, pregnancy and prior history of a cardiovascular event. Full ethical approval was 
granted (Studies; 11/NW/0090 and 13/NW/0564) and informed written consent was 
obtained from all participants. Fasting blood samples were collected in sodium citrate 
tubes following peripheral venepuncture by the clinical research team.  
The clinical research team also conducted physiological and clinical laboratory tests. A full 
assessment of disease activity, incorporating BILAG and ACR scores, was performed and 
blood samples were analysed for glucose levels, lipid profiling, erythrocyte sedimentation 
rate (ESR), complement levels and autoantibody titres. Circulating markers of inflammation 
and vascular health were assessed by ELISA kits (R&D Systems), according to 
manufacturer’s instructions(158). These were conducted in a Manchester University NHS 
Foundation Trust clinical laboratory.  
Further information regarding n numbers and tests used are located in individual chapters. 
 
2.7.1. Risk Score Calculation 
Cardiovascular risk scores were computed using online calculators indicated below. 
Following QRISK guidelines(119), in the instance of missing data, variables were left blank 
during calculation, although Framingham calculation was not possible for patients with 
missing measurements. A score of ≥10% indicated high cardiovascular risk, in accordance 
with the National Institute for Health and Care Excellence (NICE) guidelines(121). 
Online calculation tools available at:  
Framingham: https://www.framinghamheartstudy.org/fhs-risk-functions/cardiovascular-
disease-10-year-risk/   
QRISK2:  https://qrisk.org/2017/ 




2.7.2. Fatigue and Quality of Life Calculations 
The Fatigue Scale for Motor and Cognitive Functions (FSMC)(184) was utilised to assess 
fatigue levels, taking into account measures of both motor fatigue and cognition (table 2.4). 
Data pertaining to fatigue and cognitive measures were collected by Dr Michelle 
Barraclough and team. 
 
Cognitive Functions Motor Functions 
1. When I concentrate for a long time, I get 
exhausted sooner than other people of my 
age. 
1. When I am experiencing episodes of 
exhaustion, my movements become 
noticeably clumsier and less coordinated. 
2. When I am experiencing episodes of 
exhaustion, I am incapable of making 
decisions. 
2. Because of my episodes of exhaustion, I 
now need more frequent and/or longer 
rests during physical activity than I used to. 
3. Because of my episodes of exhaustion, I 
now find it more difficult to learn new 
things than I used to. 
3. When faced with stressful situations, I 
now find that I get physically exhausted 
quicker than I used to. 
4. The demands of my work exhaust me 
mentally more quickly than they used to. 
4. Because of my episodes of  exhaustion, I 
now have considerably less social contact 
than I used to. 
5. My powers of concentration decrease 
considerably when I’m under stress. 
5. I feel the episodes of exhaustion 
particularly strongly in my muscles. 
6. My thinking gets increasingly slow when 
it is hot. 
6. I no longer have the stamina for long 
periods of physical activity that I used to 
have. 
7. Because of my episodes of exhaustion, I 
now feel less like doing things which 
require concentration. 
7. When I am experiencing episodes of 
exhaustion, I am less motivated than 
others to start activities that involve 
physical effort. 
8. When I am experiencing episodes of 
exhaustion, certain words simply escape 
me. 
8. When I am experiencing an episode of 
exhaustion, my movements become 
noticeably slower. 
9. When I am experiencing episodes of 
exhaustion, I lose concentration 
considerably quicker than I used to. 
9. When an episode of exhaustion comes 
on, I am simply no longer able to react 
quickly. 
10. During episodes of exhaustion, I am 
noticeably more forgetful. 
10. When it is hot, my main feeling is one 









Table 2.4: Fatigue Scale for Motor and Cognitive Functions. The scale comprises two 
subsets of statements relating to cognitive and motor functions. Participants are required 
to rate their agreement with each statement on a 5 point Likert scale from ‘does not apply 
at all’ (1 point) to ‘applies completely’ (5 points). Scores can then be counted, with a score 
of ≥43 indicating mild, ≥53 moderate and ≥63 severe fatigue(184). 
 
 
Patients with SLE underwent further investigation, completing a Quality of Life assessment 
(LupusQoL). This test was developed from patient interviews and psychometric tests, 
resulting in a comprehensive questionnaire featuring 34 items upon a Likert scale and lower 
total scores reflecting reduced quality of life(185). 
 
 
2.8. Statistical analysis 
Statistical analysis was performed using IBM® SPSS® Statistics 25 and normality assessed 
by Kolmogorov Smirnov test; data were then analysed by parametric or non-parametric 
tests with comparison correction, as appropriate. Mean, standard deviation and standard 
error were calculated from a minimum of three data points in individual experiments, and 
a p value of ≤0.05 was considered significant. Asterisks used denote: * p≤0.05, ** p≤0.01 














The Use of Diagnostic Algorithms and Novel Biomarkers in 
Identification of Patients with SLE at High Cardiovascular Risk 
 
 
3.1. Study Introduction 
As discussed in the introductory chapter, improved detection of patients at high 
cardiovascular risk may prevent premature mortality by providing early indication for 
increased patient monitoring, evaluation of lifestyle and prescription of relevant 
treatment. Online risk calculators are available free of charge to assist with risk 
identification, while potential clinical biomarkers such as EMVs may shed light on the 
extent of vascular involvement. 
This study recruited a cohort of 138 participants, consisting of 109 patients with SLE and 29 
controls, before online Framingham, QRISK2 and QRISK3 calculators were used to predict 
cardiovascular risk, which was analysed in relation to numerous clinical measurements. The 
overall aim was to assess the use of novel and longstanding diagnostic tools, as well as 
potential biomarkers, for cardiovascular risk identification in patients with SLE. The 
objectives of this study were as follows: 
 Determine the number of patients with SLE and controls identified as having high 
cardiovascular risk using QRISK and Framingham algorithms. 
 Identify differences in traditional cardiovascular risk factors between low and high 
risk groups. 
 Analyse differences in clinical and circulating markers of inflammation, 
dyslipidaemia and vascular health between patients and controls, and low and high 
risk groups. 
 Consider the use of EMVs as biomarkers of cardiovascular risk through associations 





3.2. Chapter Methodology 
Cardiovascular risk scores were calculated as described in 2.7.1. Participants aged below 
minimum values for QRISK (25yrs; patients n=13, controls n=2) and Framingham (30yrs; 
patients n=23, controls n= 11) were entered as 25 or 30 years old respectively.  
QRISK3 risk factors, as well as clinical disease measurements and current prescription data, 
were recorded for all patients at the time of entry into the study. Additional measurements 
were taken from a subset of patients (n=58), such as EMVs, cardiovascular evaluations e.g. 
aortic pulse wave velocity (PWV), and circulating factors e.g. cytokines. EMVs were 
quantified as described in 2.3; other measurements were collected by clinical research 






No significant differences were detected between controls and patients with SLE when 
comparing basic demographic measures (table 3.1). These included traditional 
cardiovascular risk factors such as blood pressure, cholesterol, smoking status and 
diagnosis of diabetes.   
 
Variable Controls (n=29) SLE (n=109) p Values 
Age (years), mean ± SD 36.66 ± 12.95 40.75 ± 12.69 0.063 
Female 29 (100%) 105 (96.33%) 1.000 
Caucasian 23 (79.31%) 80 (73.39%) 0.634 






HDL-Cholesterol (mmol/l) 1.7 (1.5, 2.0) n=25 1.6 (1.2, 1.9) n=97 0.097 
Non-HDL Cholesterol 
(mmol/l) 
2.6 (2.3, 3.2) n=25 2.8 (2.4, 3.3)n=97 0.374 
Current Smoker 4 (13.79%) 24 (22.02%) 0.439 





Table 3.1: Demographic measures of controls and patients with SLE. Data represented as 
number (%) or median (lower and upper quartiles) unless otherwise indicated. Comparisons 
analysed by Mann-Whitney U and Fisher’s exact tests. 
 
 
3.3.2. QRISK3 Identifies More Patients at High Cardiovascular Risk Compared to 
Previous Algorithms 
QRISK2 score was significantly greater in the SLE population (p=0.001), with an average 
score of 1.8% for patients compared to 0.3% for controls (table 3.2). While the average 
control score remained unchanged when using the QRISK3 algorithm, patients exhibited a 
significant increase (p<0.001) up to 5.0%, which was, again, elevated compared to controls 
(p<0.001). A similar trend was observed using the Framingham algorithm, where patients 
possessed greater average risk scores than controls (2.2% vs 1.2%, p=0.013), which were 
still significantly lower than those calculated by QRISK3 (p<0.001). 
8 (7%) patients with SLE were determined to possess high cardiovascular risk (>10%) when 
using the QRISK2 algorithm and 5 (4.6%) when using Framingham. In contrast, QRISK3 
identified 29 (27%) patients at high risk, almost quadruple the number (p<0.001) compared 
to both QRISK2 and Framingham.  
Therefore, 21 patients were newly identified as high risk by the QRISK3 algorithm – these 
will now be referred to as the ‘missed’ patients due to their lack of recognition by the 
current QRISK2 calculator. Additionally, the missed group rose to 24 patients when 
comparing QRISK3 to Framingham; this may be of relevance to healthcare organisations 
outside the UK that are still using Framingham, however ensuing sections of this chapter 
will compare QRISK2 and 3 only. 
QRISK3 scores were also calculated without inclusion of SLE as a factor, to determine the 
impact of this additional variable in assessment of risk. This reduced the average patient 
score to 1.9% and identified 3 missed patients (not identified by QRISK2). No differences 
between QRISK2/3 or Framingham were observed in the control groups, and no missed 










QRISK2 Score (%) 0.3 (0.2, 1.9) 1.8 (0.6, 3.9) p=0.001 
QRISK3 Score (%) 0.3 (0.1, 1.7) 5.0 (3.0, 10.7) p<0.001 
QRISK2 v 3 Score  (p Values) p=0.676 p<0.001 - 
Number of High QRISK2 (n) 1 (3.45%) 8 (7.34%) p=0.458 
Number of High QRISK3 (n) 1 (3.45%) 29 (26.61%) p=0.009 
Number of High QRISK2 v 3 (p 
Value) 
p=1.000 p<0.001 - 
Missed Patients (n) 0 (0%) 21 (19.27%) p=0.007 
 
Table 3.2: Calculation of cardiovascular risk using QRISK algorithms. High risk is indicated 
by a score of ≥10%. Missed patients denoted as those identified as high risk by QRISK3 but 
low risk by QRISK2. Data represented as number (%) or median (lower and upper quartiles). 
Data analysed by Mann-Whitney U and Fisher’s exact tests. 
 
 
3.3.2.1.  Missed Patients: Differences in QRISK Factors and Medications 
High risk patients missed by QRISK2 were found to have significantly higher BMI compared 
to both controls (p=0.003) and to patients identified as low risk by both algorithms 
(p=0.026; table 3.3). The missed group also presented with elevated systolic blood pressure 
(both p<0.10) and were more likely to be experiencing chronic kidney disease (both 
p<0.05). The missed patients additionally demonstrated significantly reduced levels of HDL 
cholesterol compared to controls (p=0.037) and diagnosis of type 2 diabetes was more 
prevalent than in the low risk group (p=0.008).  
Furthermore, a greater proportion of missed patients were prescribed anti-hypertensive 
and/or oral corticosteroid treatments compared to controls and low risk patients (all 



















































































































0 (0%) 3 (14.29%) 1.000 0 (0%) 3 (14.29%) 0.008 
Rheumatoid 
Arthritis 





0 (0%) 5 (23.81%) 0.010 3 (3.75%) 5 (23.81%) 0.021 
Migraines 3 (10.34%) 1 (4.76%) 0.630 8 (10%) 1 (4.76%) 0.681 
Severe 
Mental Illness 
2 (6.90%) 2 (9.52%) 1.000 3 (3.75%) 2 (9.52%) 0.277 
Current 
Smoker 
4 (13.79%) 6 (28.57%) 0.286 
15 
(18.75%) 















0 (0%) 21 (100%) <0.001 
46 
(57.50%) 







Table 3.3: Baseline cardiovascular measures of controls, low risk and missed patients, as 
required by the QRISK3 algorithm. Variables shown as requested by the QRISK3 algorithm; 
severe mental illness inclusive of depression, schizophrenia and bipolar disorder. Data 
represented as number (%) or median (lower and upper quartiles). Comparisons analysed 
by Mann-Whitney U and Fisher’s exact test as appropriate. 
 
 
3.3.2.2.  Missed patients: Differences in SLE Factors 
Additional, SLE-specific measures were available in a reduced cohort of patients (n=71). 
When comparing these measures, fewer missed patients presented with arthritis than low 
risk patients (p=0.047) yet more were experiencing renal disease at the time of 
measurement (p=0.038; table 3.4). This figure differs from that of the chronic kidney 
disease used in QRISK calculation due to the use of the ACR criteria for SLE disease activity.  
Missed patients were additionally found to have significantly higher levels of anti-
cardiolipin antibodies compared to low risk patients (p=0.027), despite no significant 
alterations in other autoantibody titres. Current steroid prescription was also elevated in 























Disease Duration (years) 13.0 (8.0, 19.0) 12.0 (6.7, 15.0) 0.326 
ACR Criteria: Malar Rash 35 (70%) 14 (66.67%) 0.785 
ACR Criteria: Discoid Rash 25 (50%) 6 (28.57%) 0.120 
ACR Criteria: 
Photosensitivity 
34 (68%) 14 (66.67%) 1.000 
ACR Criteria: Oral Ulcers 36 (72%) 14 (66.67%) 0.777 
ACR Criteria: Serositis 15 (30%) 6 (28.57%) 1.000 
ACR Criteria: Arthritis 44 (88%) 14 (66.67%) 0.047 
ACR Criteria: Renal 
Disorder 
19 (38%) 14 (66.67%) 0.038 
ACR Criteria: Neurologic 
Disorder 
4 (8%) 2 (9.52%) 1.000 
ACR Criteria: 
Haematologic Disorder 
30 (60%) 11 (52.38%) 0.605 
ACR Criteria: Immunologic 
Disorder 
39 (78%) 14 (66.67%) 0.375 
ACR Criteria: ANA-
Positive* 
46 (94%) 18 (85.71%) 0.352 
Anti-dsDNA Antibodies* 15 (30%) 9 (42.86%) 0.429 
Anti-Cardiolipin 
Antibodies* 
4 (8%) 7 (33.33%) 0.027 
Low C3 + Low C4 Levels* 5 (10%) 2 (9.52%) 1.000 
Current Oral 
Corticosteroids 
19 (38%) 21 (100%) <0.001 
Prednisolone Dose 
(mg/day) 
7.5 (5.0, 11.3) 10 (5.5, 15.0) 0.304 
Current 
Immunosuppressive Use 
29 (58%) 13 (61.90%) 0.582 
Current Antimalarial Use 36 (72%) 17 (80.95%) 0.556 
BILAG-2004 
1.5 (0.25, 6.75) 
n=50 




2.5 (0.25, 4.0) 
n=50 




Table 3.4: Clinical and immunological measures of low risk and missed patients at point 
of entry into the study. * Indicated by laboratory reference range. Data represented as 
number (%) or median (lower and upper quartiles). Comparisons were analysed by Mann-





3.3.3. Inflammation and Vascular Dysfunction are Increased in Patients with SLE 
Results from extensive clinical and laboratory tests in a cohort of 60 patients confirmed 
increased levels of inflammation and dyslipidaemia compared to controls (n=29, table 3.5). 
Clinical indicators of inflammation, ESR and CRP were elevated in patients with SLE (both 
p<0.02), as were vascular cell adhesion molecule 1 (VCAM1), monocyte chemoattractant 
protein-1 (MCP1), IL6 and BLyS (all p<0.03). Conversely, lymphocytes were found in 
reduced numbers in patients (p=0.001), while haemoglobin and glucose levels were also 
diminished (both p<0.01). However, levels of triglycerides in the blood were increased in 
patients compared to controls (p=0.019). 
 
Variable Controls SLE p Value 
ESR (mm/hr) 6 (2, 8) 
n=25 
12 (6, 25) 
n=59 
0.013 
hsCRP (ng/ml) 0.86 (0.41, 1.20)  
n=27 
1.22 (0.62, 4.76) 
n=57 
0.006 










IL-6 (pg/ml) 0.50 0.50, 1.29)  
n=27 
1.75 (0.51, 5.39) 
n=57 
0.001 
BLyS (ng/ml) 0.34 (0.28, 0.39)  
n=27 
0.50 (0.35, 0.66) 
n=57 
<0.001 
Triglycerides (mg/dl) 0.70 (0.60, 0.80) 
n=25 
0.90 (0.60, 1.45) 
n=55 
0.019 
Lymphocytes (x10^3/µl) 1.73 (1.41, 1.87)  
n=25 
1.25 (0.97, 1.61) 
n=59 
0.001 
Haemoglobin (g/l) 132 (125, 140)  
n=25 
124 (113, 133) n=59 0.006 
Glucose (mmol/l) 4.90 (4.50, 5.10)  
n=26 




Table 3.5: Differences in clinical markers of inflammation and vascular health between 
patients and controls. N numbers provided for each variable due to cases of unobtainable 
data within groups. Variables shown chosen due to p values <0.05. Data represented as 





This patient cohort could be further subdivided into patients experiencing stable or 
exacerbated (flare) disease at time of measurement, as identified by BILAG score(112). 
Flare patients were prescribed higher doses of prednisolone and were more likely to be on 
a regimen of immunosuppressives and/or antimalarials (all p<0.05; table 3.6). No 
differences were observed in any other demographic or QRISK measurements e.g. ACR 








BILAG-2004 7 (6, 12) 1 (0, 1) <0.001 
SLEDAI-2K 6 (4, 8) 2 (0, 2) <0.001 
Prednisolone Dose (mg/day) 10.00 (6.25, 20.00) 5.00 (5.00, 7.50) 0.005 
Current Immunosuppressive 
Use 
20 (80%) 14 (40%) 0.003 
Current Antimalarial Use 21 (84%) 20 (57.14%) 0.047 
 
Table 3.6: Immunological demographics of flare and stable patients. All other 
demographic measurements p>0.05. Data represented as number (%) or median (lower and 
upper quartiles). Comparisons were analysed by Mann-Whitney U and Fisher’s exact tests. 
 
 
Within this cohort, flare patients were found to have significantly higher triglyceride levels 
than stable patients (p=0.045, table 3.7). Furthermore, platelet count was increased 
(p=0.014) alongside reduced haemoglobin levels (p=0.030), although there were no 
significant differences in incidence of haematological disorders as characterised by ACR 
criteria (p>0.05).  
 
Variable Flare Stable p Value 
Triglycerides (mg/dl) 
1.30 (0.70, 1.98) 
n=24 




259 (223, 355) 
n=25 




118 (109, 126) 
n=34 







Table 3.7: Differences in blood components between flare and stable  patients. N numbers 
provided for each variable due to cases of unobtainable data within groups. All other 
variables p>0.05. Data represented as median (lower and upper quartiles). Comparisons 
were analysed by Mann-Whitney U test. 
 
 
3.3.3.1. Inflammation and Vascular Health in Missed Patients 
Detailed laboratory results were available for a subset of low risk and missed patients, and 
demonstrated striking differences in markers of inflammation and vascular function. Once 
more, triglyceride levels showed significant variation, with higher levels in missed patients 
(p=0.017, table 3.8); mean arterial pressure (MAP) was also substantially increased 
(p<0.001). Moreover, CRP was elevated (p<0.001), whereas circulating IgM levels were 
reduced in the missed group (p=0.004). 
 
Variable Low Risk Missed p Value 
hsCRP (ng/ml) 
0.89 (0.54, 3.01) 
n=47 




1.10 (0.79, 1.48) 
n=49 




0.80 (0.60, 1.25) 
n=45 




92 (83, 96) 
n=49 




Table 3.8: Differences in clinical inflammatory and cardiovascular markers between low 
risk and missed patients. N numbers provided for each variable due to cases of 
unobtainable data within groups. All other variables p>0.05. Data represented as median 








3.3.4. Endothelial Microvesicles are Increased in SLE and are Associated with 
Inflammation, Dyslipidaemia and Vascular Dysfunction 
Numbers of circulating EMVs were enumerated within the reduced cohort described in 
3.3.3 and demonstrated significant differences according to disease, with numbers 
increased in patients compared to controls (p=0.001; figure 3.1). Furthermore, EMV 
number demonstrated a disease-dependent increase, with presence of a disease flare 
associated with increased EMV abundance compared to controls (p=0.004); abundance 




Figure 3.1: EMV abundance in SLE. Number of CD144+ microvesicles per ml of plasma were 
measured by flow cytometry in controls vs patients with SLE (A) and in controls vs stable vs 
flare patients (B). Data analysed by Mann-Whitney U (control vs SLE) and Kruskal-Wallis 
tests (controls vs stable vs flare). Asterisks used denote: * p≤0.05, ** p≤0.01 and *** 
p≤0.001. N=89; controls n=29, SLE n=60, stable n=35, flare n=25.  
 
 
Within the cohort of patients with SLE, EMV number correlated positively with ESR 
(p<0.001; table 3.9) and elevated EMVs were associated with a number of markers of 
vascular health and dyslipidaemia, including blood pressure, triglycerides and MAP (all 




of medications, namely immunosuppressives, antimalarials, steroids and the contraceptive 
pill (all p≤0.03). None of these associations were apparent in the control group. 
 
Variable Spearman rho p Value 
Haemoglobin -0.457 <0.001 
Triglycerides 0.573 <0.001 
Glucose -0.264 0.047 
ESR 0.513 <0.001 
VCAM1 0.271 0.039 
MCP1 0.426 0.001 
hsCRP 0.356 0.006 
IL6 0.418 0.001 
IgG 0.380 0.003 
Systolic BP 0.324 0.013 
MAP 0.371 0.004 
Anti-nuclear Antibodies - 0.018 




Current Antimalarial Use - 0.007 
Current Steroid Use  0.026 
 
Table 3.9: Correlations between EMV number and demographics, measures of 
inflammation and cardiovascular health in patients with SLE. N=60, all patients (no 
controls). Associations made using Spearman’s Rank Correlation Coefficient and Mann-
Whitney U test. 
 
 
3.3.5. Endothelial Microvesicles Correlate with QRISK3 Score 
EMVs were additionally connected to the cardiovascular risk algorithms, correlating 
positively with QRISK3 score across the whole cohort (controls and patients; rho:0.322, 
p=0.002) but demonstrating no such association with QRISK2 (rho:0.096, p=0.376). This 
correlation was also apparent in the missed group of patients, which demonstrated 







Figure 3.2: Correlations between EMVs and risk scores, and EMV abundance in missed 
patients. EMV number was correlated with QRISK2 (A) and QRISK3 scores (B) using 
Spearman’s Rank Correlation Coefficient; n=89 (patients and controls). Number of CD144+ 
EMVs per ml of plasma was quantified in patients with low risk and with missed high risk  
when using QRISK3 (C), with statistical analysis using Mann-Whitney U test; low risk n=50, 












3.4. Chapter Discussion 
 
3.4.1. The Use of QRISK3 Identifies an Unmet Clinical Need 
This research highlights the need for accurate diagnosis of cardiovascular risk in patients 
with SLE, who experience underlying inflammation, dyslipidaemia and vascular 
involvement, and development of novel biomarkers to improve diagnosis and monitor 
treatment strategies. QRISK2 has been established as the algorithm of choice for UK 
doctors evaluating cardiovascular risk(118), while the Framingham risk score is extensively 
used outside the UK(116). The results in section 3.3.2 demonstrate the relative inaccuracy 
of both these measures when compared to the newly developed QRISK3 algorithm, which 
identified almost four times as many high risk patients as QRISK2 and almost 6 times as 
many as Framingham. The accuracy of Framingham scores have been questioned 
previously, particularly in females and multi-ethnic communities(115, 186), as the original 
model was based on a homogenous subset of middle-aged white participants(187). 
However, the discrepancies between QRISK3 and its predecessor are interesting, arising 
from a combination of additional factors; the removal of SLE as a risk factor still resulted in 
identification of three missed patients.  
The identification of a cohort of missed patients is likely to have a resounding effect on 
patient care; indeed, the GPs of all missed patients identified in this study have been 
contacted to review treatment and monitoring of these individuals. In terms of traditional 
cardiovascular risk factors, the missed patients showed higher BMI and systolic blood 
pressure than both controls and low risk patients. Despite this, more of the missed group 
were regularly taking anti-hypertensive drugs, implying that the high cardiovascular risk 
was perhaps maintained during standard treatment. Additionally, all missed patients were 
prescribed oral corticosteroids, most likely due to dysregulated SLE symptoms. Long-term 
and, more strongly, current administration of corticosteroids have been associated with 
atherosclerosis development, particularly in SLE, in a dose-dependent manner(188-190). 
Previous data from our group demonstrated that use of the corticosteroid dexamethasone 
enhanced the osteogenic differentiation of vascular pericytes and downregulated genes 
associated with inhibition of mineralisation, highlighting the need for caution in considering 




calcification(191). Furthermore, prednisolone use by patients with SLE has been linked to 




3.4.2. Inflammatory Markers Produce a Complex Picture of Endothelial Dysfunction in 
SLE 
Lipid levels have been a predominant risk factor throughout this chapter, with missed 
patients demonstrating reduced HDL and increased triglyceride levels. Triglycerides were 
elevated in patients compared to controls, in concordance with disease activity, potentially 
indicating increased abundance of atherogenic lipoproteins such as VLDL(193, 194). 
Moreover, increased platelet counts were prominent in flare patients. This is important as 
increased platelet activation can support IFN production and endothelial dysfunction(195), 
as well as atherogenesis and plaque progression(196, 197). Anti-cardiolipin antibodies also 
interact with platelets, amplifying activation and complement deposition, activating the 
classical complement pathway and increasing the risk of thrombosis(198, 199). Although 
anti-dsDNA antibodies were consistent across low and missed groups, anti-cardiolipin 
antibodies were more prevalent in missed patients, which are further associated with 
endothelial dysfunction and thrombosis(94, 200). Thus, it becomes clear that patients with 
SLE at high risk or with high disease activity are subject to a pro-atherogenic internal 
environment, with dyslipidaemia, elevated blood pressure and pro-thrombotic circulating 
factors. 
However, this is further augmented by the dysregulated inflammatory response 
experienced by the patients in this study. CRP and ESR were both raised in patients, and 
CRP in missed patients, consistent with increased disease activity and inflammation(201, 
202); both have previously been implicated in atherosclerosis and vascular damage, for 
example through reductions in NO bioavailability(49, 203, 204). As well as acute phase 
proteins, a number of cytokines such as BLyS, IL6 and MCP-1 were found at increased levels 
in SLE, all of which have previously been suggested as biomarkers for disease activity(205-




Of note are the increased levels of VCAM-1, which have been linked to cardiovascular 
mortality and atherosclerosis in SLE(208), as well as the wider population(209). VCAM-1 is 
an adhesion molecule expressed on endothelial cells following activation by, for example, 
inflammatory cytokines, dysregulated lipid levels and oxidative stress, particularly during 
pro-thrombotic conditions, and supports leukocyte trafficking along the vascular wall(209, 
210). Nonetheless, lymphocyte count was reduced in SLE, which is common in this 
condition, and has been associated with disease activity, likely due to deficient regulatory 
T cells(211). It has also been linked to carotid intima-medial thickening in patients with 
juvenile onset SLE(212)  but a role in adults has yet to be disclosed. The reasoning behind 
lymphopenia in SLE is remains to be determined, although immunosuppressive drugs 
prescribed to patients(211) and autoantibodies targeting lymphocytes have been 
implicated(213). Haemoglobin was also reduced in SLE, consistent with disease activity, yet 
anaemia was not indicated nor were ACR-defined haematological conditions. Anaemia is 
often observed in patients with SLE, and is not uncommon in females, where it may be due 
to menorrhagia, sustained inflammation, anaemia of chronic disease, or erythropoietin 









Figure 3.3: Interplay between cytokines and acute phase proteins in SLE-related 
endothelial dysfunction. This schematic diagram introduces some of the numerous 
interactions between inflammatory mediators during atherogenesis in SLE. CRP facilitates 
opsonisation of LDL and smooth muscle cell activation, as well as endothelial dysfunction 
via upregulation of adhesion molecules, production of ROS, activation of complement 
cascade and downregulation of NO. IL-6 reinforces this by increasing CRP levels. It also 
activates B cells, endothelial cells and platelets, and promotes monocytic chemotaxis and 
smooth muscle cell proliferation. VCAM-1 and MCP1 further promote monocyte infiltration 
prior to macrophage and foam cell differentiation while BLyS stimulates B cells and supports 
production of autoantibodies. 
 
 
While the involvement of autoantibodies in SLE pathogenesis and inflammation has been 
discussed, potential protective roles for self-directed antibodies may also be considered. 
This study found significantly reduced levels of IgM in missed patients; research by Jost et 
al. highlights the involvement of antinuclear IgM antibodies in SLE disease activity but 
suggests augmented IgM-IgG class-switching and concedes a potential protective role of 
IgM(216). This is particularly prominent in vascular health, as diminished levels of IgM 
antibodies targeting phosphorylcholine, malondialdehyde and apolipoprotein antigens 
have been linked to increased risk of atherosclerotic plaque formation in SLE(217-219).  
 
 
3.4.3. The Impact of Medication: A Causal or Coincidental Link with Endothelial 
Microvesicle Release? 
Many correlations and associations between prescribed medications and markers of 
inflammation and vascular health became apparent during this study, making it difficult to 
judge whether the links were causal or coincidental. One interesting observation was 
between high EMV number and use of the contraceptive pill. Numerous clinicians hesitate 
to prescribe combined oral contraceptives to patients with SLE due to ongoing beliefs that 




animal studies and investigations into oestrogenic interactions with the immune system 
suggests a more complex picture(220). It has been suggested that prolonged use of oral 
contraceptives may support development of SLE(221), while oestrogen has been found to 
upregulate BLyS expression in a murine SLE model(222). Furthermore, oestrogen 
application appears to regulate the expression of a number of miRNAs, including miR-
126(223), which will be discussed in chapter 4, and prolonged use may promote endothelial 
dysfunction and early atherogenic changes(224). Therefore, more research into the effects 
of oral contraceptives on endothelial activation and cardiovascular risk may be prudent. 
The final medications to be discussed in this chapter are the immunosuppressives and anti-
malarials. Both were more prevalent in flare patients and linked to elevated EMVs, which 
is perhaps unsurprising as these patients experienced higher levels of inflammation and 
vascular risk. Mycophenolate mofetil and hydroxychloroquine, by far the most commonly 
prescribed immunosuppressive and anti-malarial drugs in this patient population 
respectively, have previously been independently shown to protect against endothelial 
dysfunction(103, 225) and atherosclerosis(226, 227) in murine SLE models. Thus, additional 
avenues of future research are identified, exploring the relationships between commonly 
prescribed medication and endothelial health in SLE.  
 
 
3.4.4. Endothelial Microvesicles as Potential Biomarkers of Cardiovascular Risk 
Thus far, many of the variables described could be considered future biomarkers for 
cardiovascular risk in patients with SLE due to their prominence in active disease and in 
missed high risk patients. However, it may be argued that EMVs may be more 
representative of underlying endothelial dysfunction due to their direct release from the 
endothelium itself in response to activation. Indeed, previous work by our group has 
demonstrated that increased EMVs are associated with unstable asymptomatic plaque 
formation in carotid artery disease(154) and reduced endothelial function in SLE(157), 
linking this to dysregulated inflammation(158). The current study supports the use of EMVs 
as novel biomarkers by confirming a significant increase in SLE, with correlations to more 




velocity. Furthermore, elevated EMVs were concurrent with QRISK3 score, reinforcing the 
use of both measures as indicators of cardiovascular risk.  
 
 
3.5. Chapter Summary 
 
The use of the QRISK3 algorithm identified significantly more patients with high 
cardiovascular risk than either the current QRISK2 model or another popular algorithm, the 
Framingham score. These previously missed patients differed from low risk patients and 
controls in a number of cardiovascular risk factors e.g. blood pressure, BMI.  Laboratory 
tests confirmed increased levels of inflammation and dyslipidaemia in patients with SLE 
compared to controls, which were further elevated in patients experiencing a disease flare 
or in missed high risk patients. Finally, EMV levels were significantly increased in patients 
with SLE, correlating with markers of inflammation, dyslipidaemia and vascular 
dysfunction. They also correlated with QRISK3 score, and were significantly elevated in 
missed patients.  

















  Chapter 4 
Dissecting Endothelial Microvesicle Content for the Analysis 
of Vesicular MiRNA Abundance in Patients with SLE 
 
 
4.1. Study Introduction 
As indicated in chapter 3, EMVs of patients with SLE are associated with cardiovascular risk 
alongside other elements of inflammation and disease activity. Identification of vesicular 
components demonstrating biological activity will enhance current understanding of the 
mechanisms underpinning endothelial dysfunction in SLE, as well as potentially provide 
novel targets for biomarker studies and therapeutic interventions. Due to their critical role 
in post-transcriptional gene regulation and their uptake within EMVs, this study focused on 
miRNAs in SLE, with the following aim: to establish the expression profile of circulating and 
vesicular miRNAs in patients with SLE and identify predicted targets of interest.  
This aim was addressed using the following objectives: 
 Establish a shortlist of miRNAs to screen by data mining. 
 Assess miRNA abundance in an in vitro model of the SLE endothelium. 
 Determine levels of miRNA abundance in the vesicular fraction of plasma from 
patients and controls. 
 Correlate miRNA abundance with clinical markers of inflammation and 
cardiovascular risk. 










4.2. Chapter Methodology 
 
Firstly, key miRNAs were identified by extensive data mining and shortlisting, dependent 
on a number of factors such as available data and novelty. To model the inflammatory 
environment surrounding the vascular endothelium in SLE, HUVECs at passage 4-6 were 
then treated for 24 hours with either 10ng/ml TNFα, BLyS or both. EMVs were obtained 
from the media, as described in 2.3.1, and miRNA extracted as in 2.4.2; intracellular miRNA 
was also extracted. Next, key miRNAs were quantified in order to provide insight into 
miRNA trafficking during inflammation. 
In order to ascertain whether the results noted during the in vitro testing correlated with 
in vivo observations, the vesicular fraction of 1ml plasma was isolated and miRNA 
quantified. 14 control and 26 patients with SLE (15 with stable and 11 with flared disease) 
were included in this study, with recruitment as defined in 2.7. Inclusion was dependent on 
plasma stores remaining from the analysis described in chapter 3. Following qPCR, 
associations between miRNA expression levels and clinical data were probed, as in chapter 
3. Full miRNA protocols are located in section 2.4. Finally, predicted targets were 
determined using the gene ontology techniques described in 2.4.4, excluding ‘cellular 
respiration’, which was performed in later chapters. The workflow for this body of research 








Figure 4.1: Workflow for elucidation of miRNA contents and predicted targets in 





4.3.1. MiRNA Abundance within HUVECs and EMVs Released after Treatment with TNFα 
and BLyS 
Cytokine treatment was used to determine miRNA abundance in a model of the inflamed 
endothelium. HUVECs were treated with either TNFα, BLyS or an equal mix of both, and 
the amounts of target miRNAs within the cells and in vesicles extracted from the media 
were quantified. The data shown in figure 4.2 represent miR-320a abundance as other 





Interestingly, when HUVECs were treated with inflammatory cytokines, miR-320a 
abundance decreased, most significantly following TNFα treatment (p=0.010). A similar 
trend was apparent with BLyS (p=0.020) and mixed treatments (p=0.015), although an n=2 
for these samples prevented statistical analysis. The opposite effect was observed in the 
microvesicles produced, which yielded increased miR-320a abundance in response to TNFα 
(p=0.026) but no change in response to BLyS (p=0.150) or mixed treatment (p=1.000). 
 
 
Figure 4.2: Endothelial miR-320a abundance following cytokine treatment. Confluent 
HUVECs were treated for 24 hours at p4-6 with 10ng/ml TNF-α, BLyS or a mix of both, before 
vesicular and intracellular miR-320a was quantified. N=3 in control and TNF-a treated cells, 
and n=2 in BLyS and mixed treatment cells. Statistical analyses performed using one-way 




4.3.2. Demographic Details of Patients used in this Study 
Plasma samples from this subset (n=40) of the original cohort of participants (n=138) 
introduced in chapter 3 were utilised in this study. Demographic measures were generally 
similar between controls and patients with SLE, although the control group were younger 
in age; 36.50 (± 13.61) for controls vs 42.58 (± 10.11) of patients with SLE (p=0.023; table 
4.1). However, there was substantial variation in age across both groups, therefore it was 
deemed acceptable to continue the study. The SLE group also demonstrated higher QRISK3 
scores (p<0.001), which is consistent with the results of chapter 3. There were no significant 
differences in demographic measures when the patient group was further subdivided into 
those experiencing flared and stable disease. 
 
Variable Controls (n=14) SLE (n=26) p Values 
Age (years), mean ± SD 36.50 ± 13.61 42.58 ± 10.11 0.023 
Female 14 (100%) 25 (96.15%) 1.000 
Caucasian 11 (78.57%) 17 (65.38%) 0.484 
BP Systolic (mm Hg) 
120.0 (115.0, 130.0) 
n=13 
126.0 (122.0, 137.0) 
n=25 
0.199 
HDL-Cholesterol (mmol/l) 1.6 (1.5, 2.0) 1.7 (1.2, 2.0) n=25 0.613 
Non-HDL Cholesterol 
(mmol/l) 
2.7 (2.5, 3.4) 2.8 (2.5, 3.2) n=25 0.897 
Current Smoker 1 (7.14%) 2 (7.69%) 1.000 
Type 2 Diabetes 0 (0%) 0 (0%) 1.000 
QRISK3 Score (%) 0.3 (0.1, 0.4) 5.4 (3.4, 8.9) <0.001 
High QRISK3 0 (0%) 6 (23.08%) 0.074 
 Flare (n=11) Stable (n=15) p Values 
Age (years), mean ± SD 43.09 ± 7.90 42.20 ± 11.45  0.721 
Female 11 (100%) 14 (93.33%) 1.000 
Caucasian 7 (63.64%) 10 (66.67%) 1.000 
BP Systolic (mm Hg) 
128.0 (121.5, 137.0) 124.5 (122.3, 132.5) 
n=14 
0.536 
HDL-Cholesterol (mmol/l) 1.5 (1.0, 1.9) 1.8 (1.4, 2.1) n=14 0.120 
Non-HDL Cholesterol 
(mmol/l) 
3.1 (2.6, 4.0) 2.6 (2.3, 3.1) n=14 0.403 
Current Smoker 0 (0%) 2 (13.33%) 0.492 
Type 2 Diabetes 0 (0%) 0 (0%) 1.000 
QRISK3 Score (%) 6.3 (4.7, 9.8) 5.0 (2.3, 8.4) 0.281 





Table 4.1: Demographic measures of controls and patients with SLE included in miRNA 
cohort. Data represented as number (%) or median (lower and upper quartiles).  P values 
calculated by Mann-Whitney U test or Fisher’s exact test, as appropriate. 
 
 
4.3.3. Vesicular MiRNA Abundance is Altered in SLE 
Seven miRNAs of interest were investigated, firstly by general abundance within the 
vesicular fraction of plasma (table 4.2). These miRNAs had been selected through data 
mining, which is further examined in discussion section of this chapter. Levels of both miR-
126-3p and miR-3148 appeared to be increased in the plasma of patients with SLE 
compared to controls (2.29-fold and 6.31-fold respectively).  
 
MiRNA Control  SLE  SLE Fold Control 
MiR-126-3p 2.5E-09 5.8E-09 2.29 
MiR-3148 1.1E-12 6.6E-12 6.31 
MiR-93-5p 3.6E-09 2.9E-09 0.81 
MiR-320a 2.6E-09 3.4E-09 1.34 
MiR-30d-5p 1.7E-09 1.8E-09 1.04 
MiR-15b-5p 2.3E-09 3.8E-09 1.66 
MiR-20a-5p 9.4E-09 1.3E-08 1.37 
 
Table 4.2: Plasma abundance of vesicular miRNAs. Abundance presented as calculated by 
2-ΔΔCt method following QPCR. Control n=14, SLE n=26.  
 
 
Chapter 3 described elevated numbers of EMVs in the circulation of the patient group, 
therefore let-7a was chosen to act as a ‘housekeeper’ to normalise levels of miRNA 
abundance. Levels of let-7a showed a trend towards an increase in patients compared to 
controls, although this was not significant (p=0.154; figure 4.3). Likewise, let-7a abundance 
was not significantly increased in patients experiencing flared (p=0.064) or stable (p=1.000) 




There were no differences in let-7a abundance per microvesicle in patients vs controls 
(p=0.900) nor when comparing any other group (controls vs stable p=1.000, control vs flare 
p=0.935, stable vs flare p=0.346).  Thus, it was decided to present the miRNA abundance 





Figure 4.3: Abundance of let-7a in plasma samples. Abundance of let-7a was quantified in 
1ml of plasma and analysed per ml (A) and per microvesicle (B). Comparisons between 
controls and all patients assessed by Mann-Whitney U test, and between controls and 
disease activity (stable and flare) by Kruskal-Wallis test. Error bars represent SEM. Control 








4.3.4. Identifying an SLE MiRNA Signature: Increased MiRNA Abundance 
4.3.4.1. MiR-126-3p is Associated with SLE Disease Flares 
A trend towards increased abundance of miR-126-3p was observed in patients compared 
to controls, significantly so with patients experiencing flared disease (figure 4.4). This was 
the case when analysing abundance per ml of plasma (p=0.001), relative to let-7a (p=0.024) 
and per microvesicle (p=0.009). Abundance was also consistently higher in patients with 
flared compared to stable disease (p=0.002, p=0.0.19 and p=0.001 respectively). There 
were no differences in stable patients compared to controls (p=1.000 for all measures), nor 






Figure 4.4: MiR-126-3p abundance in plasma vesicular fractions. Abundance of miR-126-
3p was measured in participants by qPCR and compared against volume of plasma (A), 
relative let-7a abundance (B) and per microvesicle (C). Comparisons between controls and 
all patients assessed by Mann-Whitney U test, and between controls and disease activity 
(stable and flare) by Kruskal-Wallis test. Error bars represent SEM. Control n=14, SLE n=26, 





When miR-126-3p abundance was correlated with clinical data (table 4.3), increased levels 
correlated positively with QRISK2 and 3 scores (p<0.05), as well as EMV number (p<0.01). 
Increased abundance also correlated with increased age (p<0.04), cholesterol/HDL ratio 
(p<0.05), adiponectin (p=0.025) and BLyS levels (p=0.024), although a negative correlation 
was observed with haemoglobin (p=0.020). Furthermore, increased miR-126-3p 
abundance was associated with anti-hypertensive (p<0.05) and statin use (p=0.047). In the 
patient cohort only, miR-126-3p correlated negatively with both IgM (p=0.001) and 
anticardiolipin IgM antibodies (p=0.039), and was associated with renal disorder (p<0.040) 













































































































8.8x10-9 ± 1.0x10-8 
4.2x10-9 ± 7.0x10-9 
p=0.034 
9.6 ± 11.8 
2.3 ± 3.6 
p=0.009 
5.7x10-16 ± 6.3x10-16 








1.0x10-8 ± 9.2x10-9 
2.7x10-9 ± 5.7x10-9 
p=0.001 
10.0 ± 10.9 
2.8 ± 6.3 
p=0.001 
9.9x10-16 ± 1.1x10-15 






6.1x10-9 ± 4.3x10-9 
4.4x10-9 ± 7.9x10-9 
p=0.279 
7.5 ± 4.1 
4.2 ± 8.9 
p=0.047 
1.1x10-15 ± 1.4x10-15 








8.3x10-9 ± 9.4x10-9 
1.0x10-9 ± 2.9x10-9 
p=0.047 
6.8 ± 9.4 
1.0 ± 2.7 
p=0.035 
7.0x10-16 ± 9.0x10-16 
6.4x10-17 ± 1.6x10-16 
p=0.082 
 
Table 4.3: Associations between miR-126-3p abundance and clinical data. Renal disorder 
characterised by ACR criteria. Upper section presents Spearman’s rho correlation 
coefficients; lower section presents mean expression (± standard deviation) with statistical 
analysis using Mann-Whitney U test. Comparisons made across whole cohort unless 




An investigation into the targets of miR-126-3p yielded a predicted binding score of 0.999 
(maximum 1) for epidermal growth factor receptor (EGFR), the highest score with this 
miRNA (table 4.4). This was listed under ‘ossification’ by the GO consortium and yielded 
the largest node degree on Cytoscape, indicating its importance in a variety of processes 
other than osteogenesis. Other highly likely targets included vascular endothelial growth 
factor receptor 3 kinase (FLT4), cyclooxygenase 2 (PTGS2) and platelet derived growth 
factor receptor-α (PDGFRA), which are implicated in vascular function and SLE-related 
inflammation.  
 






EGFR Ossification 1/974 0.999 
CD44 SLE N/A 0.960 
FLT4 Angiogenesis 931/12 0.959 
DICER1 Angiogenesis 180/97 0.941 
CREB1 SLE N/A 0.935 
CSF1 Ossification 96/51 0.922 
SMAD4 EC activation 2/230 0.900 
MS4A1 SLE N/A 0.898 
PTGS2 SLE N/A 0.894 
PDGFRA Angiogenesis 302/56 0.892 
 
Table 4.4: Highest ranking predicted targets of miR-126-3p. Data ranked by DIANA miTG 
score of predicted binding, supported by cytoscape ranking and node degree (corresponding 













4.3.4.2. MiR-3148 is Increased in SLE and has Predicted Ossification Targets 
Although miR-3148 was detected at lower levels than the other miRNAs, expression per ml 
of plasma was significantly elevated in patients with SLE (p=0.009; figure 4.5). This was also 
significant in stable disease compared to controls (p=0.012) and demonstrated a trend in 
flared disease (p=0.094); there was no difference between flared and stable disease 
(p=1.000). Similarly, trends towards increased abundance in SLE were apparent but not 
significant when analysing levels relative to let-7a (p=0.162) and per microvesicle 
(p=0.279). Nor were there any differences according to disease activity when relative to 
let-7a (control vs stable p=0.214, control vs flare p=1.000, flare vs stable p=0.698) or per 







Figure 4.5: MiR-3148 abundance in plasma vesicular fractions. Abundance of miR-3148 
was measured in participants by qPCR and compared against volume of plasma (A), relative 
let-7a abundance (B) and per microvesicle (C). Comparisons between controls and all 
patients assessed by Mann-Whitney U test, and between controls and disease activity 
(stable and flare) by Kruskal-Wallis test. Error bars represent SEM. Control n=14, SLE n=26, 







Elevated miR-3148 abundance per ml of plasma was associated with increased QRISK3 
score and EMV number (p<0.03; table 4.5), whereas abundance per microvesicle correlated 
negatively with PMVs (p=0.024). Abundance also correlated negatively with glucose 
(p<0.04) and positively with MCP-1 (p=0.035). Furthermore, it was associated with ACR 
































































3.1x10-9 ± 4.7x10-9 
2.8x10-9 ± 2.8x10-9 
p=0.003 
3.2 ± 3.3 
2.2 ± 1.5 
p=0.001 
1.7x10-18 ± 1.1x10-18 
3.8x10-19 ± 5.1x10-19 
p=0.009 
 
Table 4.5: Associations between miR-3148 abundance and clinical data. Serositis 
characterised by ACR criteria. Upper section presents Spearman’s rho correlation 
coefficients; lower section presents mean expression (± standard deviation) with statistical 
analysis using Mann-Whitney U test. Comparisons made across whole cohort unless 






One possible target of miR-3148, insulin-like growth factor 1 (IGF1) yielded the maximum 
possible binding score of 1.000, indicating certain binding (table 4.6); this was associated 
with ossification, as was RUNX2 (0.999).  
 






IGF1 Ossification 158/26 1.000 
RHOA Angiogenesis 199/88 0.999 
SATB2 Ossification 118/40 0.999 




PTPRB Angiogenesis 457/34 0.996 
PDPK1 Angiogenesis 267/63 0.992 
INTU Ossification 178/21 0.991 
MBL2 SLE Na 0.991 
MEIS1 Angiogenesis 737/18 0.990 
 
Table 4.6: Highest ranking predicted targets of miR-3148. Data ranked by DIANA miTG 
score of predicted binding, supported by cytoscape ranking and node degree (corresponding 

















4.3.5. Identifying an SLE MiRNA Signature: Decreased MiRNA Abundance 
4.3.5.1. Mir-93-5p Abundance is Significantly Reduced in SLE 
While abundance of miR-93-5p per ml of plasma appeared to be reduced in patients 
compared to controls (p=0.130), it was significantly so when relative to let-7a (p=0.018) 
and per microvesicle (p=0.015; figure 4.6). Indeed, while no differences were observed in 
miRNA abundance per ml of plasma (controls vs stable p=0.275, controls vs flare and flare 
vs stable both p=1.000), abundance relative to let-7a was significantly decreased in patients 
experiencing a disease flare compared to controls (p=0.043). There were no differences in 
flare vs stable patients (p=1.000) nor in stable patients vs controls, despite an apparent 
trend towards a reduction (p=0.270). Conversely, miR-93-5p abundance per microvesicle 
was significantly reduced in stable patients compared to controls (p=0.049) but not in flare 






Figure 4.6: MiR-93-5p abundance in plasma vesicular fractions. Abundance of miR-93-5p 
was measured in participants by qPCR and compared against volume of plasma (A), relative 
let-7a abundance (B) and per microvesicle (C). Comparisons between controls and all 
patients assessed by Mann-Whitney U test, and between controls and disease activity 
(stable and flare) by Kruskal-Wallis test. Error bars represent SEM. Control n=14, SLE n=26, 






Across the whole cohort, abundance of miR-93-5p correlated negatively with both EMVs 
and PMVs (p<0.04), as well as MCP-1 (p<0.05) and positively with glucose (p<0.02; table 
4.7). Moreover, within the patient population, it was associated with neutrophil number, 


























































3.4x10-9 ± 4.1x10-9 
2.4x10-9 ± 2.6x10-9 
p=1.000 
1.3 ± 0.9 
3.5 ± 2.4 
p=0.003 
2.4x10-16 ± 2.6x1016 
3.1x10-16 ± 3.3x10-16 
p=0.681 
 
Table 4.7: Associations between miR-93-5p abundance and clinical data. Haematologic 
disorder characterised by ACR criteria. Upper section presents Spearman’s rho correlation 
coefficients; lower section presents mean expression (± standard deviation) with statistical 
analysis using Mann-Whitney U test. Comparisons made across whole cohort unless 









Sortilin 1 (SORT1) was the highest ranking potential target of miR-93-5p, with a predicted 
binding score of 0.962 (table 4.8). While the GO consortium identified SORT1 as implicated 
in ossification, many high-ranking targets were involved in angiogenesis, such as hypoxia 
inducible factor 1-α (HIF1A; 0.940), STAT3 (0.914) and matrix metalloproteinase 2 (MMP2; 
0.901).  
 






SORT1 Ossification 28/147 0.962 
RASSF2 Ossification 76/65 0.962 
HIF1A Angiogenesis 52/256 0.940 
PIAS2 Ossification 35/125 0.927 
STAT3 Angiogenesis 36/326 0.914 
EPHB4 Angiogenesis 856/14 0.910 
GAB1 Angiogenesis 34/331 0.904 




CNOT7 IFNA Signalling 32/45 0.860 
 
Table 4.8: Highest ranking predicted targets of miR-93-5p. Data ranked by DIANA miTG 
score of predicted binding, supported by cytoscape ranking and node degree (corresponding 















4.3.5.2. MiR-320a is Reduced in SLE and May Target Pathways Involved in 
Angiogenesis and Ossification 
Abundance of miR-320a per ml of plasma (p=0.856) and relative to let-7a (p=0.154) 
revealed contrasting trends, with no clear pattern detected until analysis of abundance per 
microvesicle, which was significantly reduced in patients compared to controls (p=0.045; 
figure 4.7). No other differences were detected, in either abundance per ml (all p=1.000), 
relative to let-7a (controls vs flare p=0.110, controls vs stable p=1.000, flare vs stable 







Figure 4.7: MiR-320a abundance in plasma vesicular fractions. Abundance of miR-320a 
was measured in participants by qPCR and compared against volume of plasma (A), relative 
let-7a abundance (B) and per microvesicle (C). Comparisons between controls and all 
patients assessed by Mann-Whitney U test, and between controls and disease activity 
(stable and flare) by Kruskal-Wallis test. Error bars represent SEM. Control n=14, SLE n=26, 








While miR-320a abundance correlated with fewer clinical measures than the other miRNAs 
(table 4.9), it did demonstrate negative correlations with both EMVs and PMVs across the 
whole cohort of participants (p<0.05), whereas in patients, it was associated with 




































5.1x10-9 ± 4.2x10-9 
2.4x10-9 ± 1.6x10-9 
p=0.235 
1.5 ± 2.0 
6.9 ± 1.5 
p=0.297 
7.1x10-16 ± 5.4x10-16 
3.7x10-16 ± 2.4x10-16 
p=0.036 
 
Table 4.9: Associations between miR-320a abundance and clinical data. Upper section 
presents Spearman’s rho correlation coefficients; lower section presents mean expression 
(± standard deviation) with statistical analysis using Mann-Whitney U test. Comparisons 
made across whole cohort unless otherwise stated. Control n=14, SLE n=26. 
 
 
The highest ranking predicted targets often fell within the fields of ‘angiogenesis’ and 
‘ossification’ and many were associated with smaller nodes, as ranked by Cytoscape (table 
4.10). The highest predicted targets were matrix metalloproteinase 16 (MMP16; 0.991), 
cyclin-dependent kinase 6 (CDK6; 0.990) and bone morphogenic protein receptor type 1α 














MMP16 Ossification 420/0 0.991 
CDK6 Ossification 22/170 0.990 
BMPR1A Ossification 102/48 0.987 
IRF6 IFNA signalling 83/5 0.975 
HOXA5 Angiogenesis 1080/9 0.974 
MAP3K7 Angiogenesis 337/50 0.973 
NFATC3 Angiogenesis 1240/6 0.970 
NR3C1 SLE na 0.967 
PRCP Angiogenesis 1327/5 0.964 
SASH1 Angiogenesis 1493/4 0.959 
 
Table 4.10: Highest ranking predicted targets of miR-320a. Data ranked by DIANA miTG 
score of predicted binding, supported by cytoscape ranking and node degree (corresponding 




4.3.5.3. MiR-30d-5p is Reduced in SLE and Associated with Markers of 
Inflammation and Dyslipidaemia 
The final miRNA to be analysed was miR-30d-5p (figure 4.8). Abundance of this miRNA 
demonstrated no differences when analysed per ml of plasma (controls vs SLE p=0.769, 
controls vs stable p=0.275, controls vs flare and flare vs stable both p=1.000). However, 
when abundance was analysed relative to let-7a and per microvesicle, it was significantly 
reduced in patients with SLE compared to controls (p=0.025 and p=0.029 respectively). 
When analysed relative to let-7a, abundance was further reduced in flare patients 
compared to controls (p=0.043) but not in stable patients (p=0.270) nor in flare vs stable 
patients (p=1.000). This was reversed when analysed per microvesicle, such that 
abundance was lowest in stable patients compared to controls (p=0.049) but no differences 






Figure 4.8: MiR-30d-5p abundance in plasma vesicular fractions. Abundance of miR-30d-
5p was measured in participants by qPCR and compared against volume of plasma (A), 
relative let-7a abundance (B) and per microvesicle (C). Comparisons between controls and 
all patients assessed by Mann-Whitney U test, and between controls and disease activity 
(stable and flare) by Kruskal-Wallis test. Error bars represent SEM. Control n=14, SLE n=26, 
stable n=15, flare n=11. * denotes p≤0.05. 
 
MiR-30d-5p abundance correlated with a number of clinical markers such as cholesterols 
and both EMVs and PMVs (p<0.05; table 4.11). Within the patient cohort, abundance 




anticardiolipin IgM molecules (p=0.008). Furthermore, abundance was associated with 














































































2.0x10-9 ± 1.3x10-9 
8.5x10-10 ± 7.1x10-10 
p=0.057 
1.8 ± 1.0 
2.5 ± 2.2 
p=0.659 
2.1x10-16 ± 1.5x10-16 








2.1x10-9 ± 1.6x10-9 
1.4x10-9 ± 9.5x10-19 
p=0.274 
1.3 ± 1.0 
2.4 ± 1.4 
p=0.006 
2.0x10-16 ± 1.6x10-16 
1.8x10-16 ± 1.4x10-16 
p=0.797 
 
Table 4.11: Associations between miR-30d-5p abundance and clinical data. 
Photosensitivity and haematology disorder characterised by ACR criteria. Upper section 
presents Spearman’s rho correlation coefficients; lower section presents mean expression 
(± standard deviation) with statistical analysis using Mann-Whitney U test. Comparisons 





The highest ranked predicted targets were associated with a range of GO consortium areas, 
but three demonstrated the highest predicted binding score of 1 (table 4.12). These were 
beclin 1 (BECN1), SNAI1/snail and suppressor of cytokine signalling 1 (SOCS1). Cytoscape 
data were unavailable for SOCS1, however, both BECN1 and SNAI1 showed large nodes of 
350 and 177 degrees respectively. Other predicted targets included RUNX2 (0.998) and 
angiomotin-like protein 2 (AMOTL2; 0.997).  
 






BECN1 Angiogenesis 29/350 1.000 
SNAI1 Ossification 20/177 1.000 
SOCS1 SLE na 1.000 
RUNX2 Ossification 150/27 0.998 




EFNA Angiogenesis 847/14 0.994 
KLF10 Ossification 196/17 0.991 
SH2B3 Angiogenesis 973/11 0.990 
HDAC5 Angiogenesis 365/45 0.988 
 
Table 4.12: Highest ranking predicted targets of miR-30d-5p. Data ranked by DIANA miTG 
score of predicted binding, supported by cytoscape ranking and node degree (corresponding 
with number of networks and connections to other cellular pathways). 
 
 
4.3.6. Additional MiRNA Analysis 
A further two miRNAs were tested, namely miR-15b-5p and miR-20a-5p. They both 
demonstrated similar patterns of increase in SLE, particularly in disease flares, but no 
statistical significance between when analysing abundance levels per ml of plasma 
(p=0.644 and p=0.747 respectively; figure 4.9). This was mirrored in abundance relative to 
let-7a and per microvesicle, which demonstrated the same weak trends without 
significance for both miR-15b-5p (p=0.266 and p=0.604) and miR-20a-5p (p=0.424 and 




stable and flared disease across any measure (p>0.05; data not shown). Thus it was decided 
to discontinue further work with these miRNAs, instead focussing on those with stronger 




Figure 4.9: MiR-15b-5p and miR-20a-5p abundance in plasma vesicular fractions. 
Abundance of miR-15b-5p (A) and miR-20a-5p (B)was measured in participants by qPCR 
and compared against volume of plasma. Comparisons between controls and all patients 
assessed by Mann-Whitney U test, and between controls and disease activity (stable and 









4.4. Chapter Discussion 
 
4.4.1. Rationale for MiRNA Selection 
The presence of miRNA within extracellular vesicles has been previously documented, 
suggesting a mode of action by which vesicles may interact with and affect the function of 
the endothelium(125, 136, 137). This study interrogated the expression of seven miRNAs 
associated with microvesicles in the circulation of patients with SLE, all of which were 
carefully selected in order to build a panel of both disease-relevant and interesting targets. 
MiR-126-3p was the first to be chosen as it is implicated in both SLE and CVD; a number of 
papers have documented increased levels in SLE and other autoimmune diseases(228, 
229), while Jansen et al. found it predicted a reduced risk of a major adverse cardiovascular 
event in patients with coronary artery disease(230), and described its role in endothelial 
repair(231). These studies affirm that it has been isolated from EMVs both in vivo and in 
vitro, and furthermore, previous unpublished work by our group found increased levels 
following BLyS stimulation in an in vitro endothelial model. MiR-126-3p was therefore 
included to validate and build on previous research using this patient cohort. 
In contrast, miR-93-5p was chosen as a novel, less well understood miRNA. It had previously 
been isolated from plasma and it was suggested to be an independent predictor of stroke 
and coronary artery disease(151, 152), yet little was known about its activity in SLE. Thus, 
it presented an opportunity for novel data combining cardiovascular effects in SLE. 
Even less was known about miR-3148 at the time of experimentation, although earlier 
unpublished data by our group observed its presence within EMVs and positive effects on 
vascular calcification. It was included in this study to advance the knowledge base and 
investigate its effects upon the endothelium. MiR-3148 has also been associated with toll 
like receptor expression in SLE, albeit in peripheral blood mononuclear cells(232).  
MiR-30d-5p was likewise associated with calcification(233), as well as heart failure(234), 
but its endothelial effects have not, to our knowledge, been described. More had been 
documented regarding miR-320a in CVD, including endothelial interactions and presence 




events(237, 238). Consequently, miR-30d-5p and miR-320a were both chosen in order to 
characterise this expression profile and fill the knowledge gaps.   
MiR-15b-5p showed promise in the selection stage, as an upregulation in plasma from 
patients with SLE had previously been detected(239), and a potential pathway of 
angiogenic repression suggested(240, 241), thus inviting the elucidation of the molecular 
mechanisms underpinning its endothelial effects in SLE. MiR-20a-5p was also selected, as 
an unpublished preliminary screen had associated it with vascular calcification, a pathology 
of interest in our group and also prevalent in SLE(242).However, neither of these miRNAs 




4.4.2. The Use of an In Vitro Model for Studying MiRNA Abundance 
Prior to quantification in patient plasma, miRNA abundance was measured following 
cytokine treatment of endothelial cells in vitro. This was intended to model the 
inflammatory environment of SLE, and to confirm miRNA presence in EMVs and compare 
this to intracellular abundance. The low levels of the miRNAs selected prevented full 
quantification of all except one – miR-320a. Following treatment with TNFα, abundance of 
miR-320a in endothelial cells decreased significantly, mirroring the situation in patients 
with SLE described in this chapter. In this way, the inflammatory model appeared to reflect 
the situation in vivo. However, an interesting point was the increase in vesicular miR-320a 
abundance following the same treatment, potentially indicating a deliberate shuttling of 
this miRNA into the vesicles for their release. It is unclear whether this is a protective 
mechanism to rid the cell of a potentially harmful overload or if the miRNA-loaded vesicles 
serve another purpose, perhaps affecting another cell type; while functional analysis, as in 
the following chapters, may provide an indication of function, further investigation is 
needed to define the role of miR-320a in disease, and whether cellular models can 
accurately reflect patient studies. Nevertheless, this preliminary test confirmed the release 





When conducting the in vitro experiments, miRNA abundance was analysed relative to 
control cells, and it was clear that the vesicles isolated would be of endothelial origin as 
only endothelial cells had been included. This was not the case with the patient studies, as 
while abundance per ml was the simplest form of analysis, it did not reflect the increase in 
EMVs detected in the patient group. Accordingly, a housekeeping miRNA was considered, 
as is often the case in standard qPCR(243). Let-7a was selected for this study as its suitability 
as a reference gene has been previously considered by other groups (172, 173, 175, 176), 
however the trend in let-7a abundance in this study did not appear to be constant across 
participants. Nevertheless, the pattern was not significantly different; it may have been 
reflective of disease activity or another mechanism not studied here, so analysis relative to 
let-7a was continued, also to control for small differences in miRNA extracted. There 
remains a lack of consensus regarding housekeeping genes in miRNA analysis and the 
validity of using any one gene is questioned by the constantly evolving field(174); let-7a has 
since been implicated in angiogenesis(244, 245) and therefore, it was decided to further 
analyse the miRNA abundance per microvesicle. By doing this, another method of control 
was incorporated, yet it also reflected the fact that microvesicles from other cellular 
sources would have been present in the plasma, such as PMVs. 
 
 
4.4.3. Increased Abundance of Key MiRNAs in SLE May Support Biomarker Development 
The mode of analysis did not appear to make a difference in analysis of miR-126-3p 
abundance, as the same pattern was apparent across all methods; significantly increased 
levels in patients experiencing a disease flare. Consequently, it may be inferred that miR-
126-3p abundance is linked to increased disease activity, which is supported by the 
understanding that this miRNA leads to increased autoreactivity through T cell 
activation(246). It cannot be known whether the increased inflammation upregulates miR-
126-3p abundance or vice versa, but this is an area for further study; it is possible that they 
perpetuate each other. Indeed, miR-126-3p was associated with increased QRISK score and 
EMV release, as well as BLyS and IgM levels, and dyslipidaemia as measured by cholesterol 




medical treatment, further indication of its relationship with active disease. A range of 
potential targets of miR-126-3p were identified; EGFR had the highest miTG score and is 
involved in vascular calcification through activation and migration of smooth muscle 
cells(247). Inhibition of EGFR in a murine model led to attenuated vascular inflammatory 
responses, smooth muscle cell proliferation and progression of atherosclerosis(248), which 
suggests the overabundance of this miRNA may be a protective mechanism in the context 
of SLE. 
While miR-3148 abundance in patient plasma was elevated compared to controls, a similar 
trend was observed in abundance relative to let-7a and per microvesicle. The actual levels 
of this miRNA were extremely low, yet the difference in detectability between patients and 
controls demonstrates promise in its use as a biomarker i.e. if it is only detectable in people 
with SLE. Consequently, abundance correlated with relevant markers of inflammation and 
cardiovascular risk – QRISK3, EMVs, MCP-1 and ACR count. It also correlated negatively 
with glucose, implying another role in glucose homeostasis that is beyond the scope of this 
research. The increase in patients with serositis is interesting and may be significant; 
alternatively it may simply reflect the exacerbated disease and inflammation. It is also 
worth stressing that while serositis in SLE often refers to pleurisy, it conjointly encompasses 
pericarditis at a similar population rate(249); this may be part of the link between miR-3148 
and cardiovascular dysfunction. As with miR-126-3p, the upregulation of miR-3148 may be 
a protective mechanism to counter the damaging inflammation, as inhibition of some of its 
key predicted targets may preserve vascular integrity and function; the pleotrophic effects 
of IGF1 are controversial but certain polymorphisms have been implicated in 
atherosclerosis(250, 251) whereas other studies suggest a beneficial role in 
angiogenesis(252, 253). Furthermore, inhibition of RUNX2 and MBL2 supports reduced 
vascular calcification and depressed thrombogenicity(254, 255).  
Both of these miRNAs were associated with anticardiolipin antibodies, which have been 
previously linked to thrombosis and plaque progression, although the immunoglobulin 
isotype appears important in the potential function of these antibodies. It is interesting to 
consider why the two miRNAs with increased abundance in SLE demonstrate negative 
correlations with anticardiolipin antibodies(79, 94), while those that are decreased are also 








4.4.4. The SLE Signature Contains Key MiRNAs at Reduced Levels 
MiR-93-5p abundance was reduced in patients, albeit only when analysing relative to let-
7a and per microvesicle. This highlights the difficulty in establishing a mode of analysis that 
takes into account the increased endothelial activation (and EMV release) in SLE and the 
necessity for consideration in future biomarker development. These data seem to suggest 
that while each vesicle (both endothelial and platelet-derived) may contain less miR-93-5p, 
the general plasma abundance is similar to that of controls due to the cumulative effect of 
increased microvesicle numbers. The associations with MCP-1, IgM and neutrophils 
insinuates a link to inflammation but whether this is coincidental or causative is difficult to 
tell – and if it is causative, is it protective or damaging? Predicted targets such as HIF-1α 
and MMP2 support the theory of miR-93-5p as atheroprotective(97, 256, 257); in this case, 
the downregulation of this miRNA in SLE may consequently result in increased 
inflammation and endothelial dysfunction. The highest ranking predicted target sortilin-1 
is a known cardiovascular risk gene, promoting dyslipidaemia through lipoprotein uptake 
and transport(258). Thus, if miR-93-5p cannot bind and inhibit these targets, due to its own 
downregulation, patients may be at increased risk of atherogenesis. 
Plasma abundance levels of both miR-30d-5p and miR-320a were variable and inconclusive, 
however miR-30d-5p demonstrated reduced levels in patients, relative to let-7a and per 
microvesicle, and miR-320a yielded the same per microvesicle only. It is therefore perhaps 
unsurprising that both were associated with microvesicle number (both EMV and PMV), 
although miR-30d-5p was also associated with a number of other factors. Negative 
correlations with cholesterol markers supported its implications in cardiovascular disease, 
while positive relationships with number of symptomatic years and haemoglobin, as well 
as negative correlations with white blood cells, affiliated it with disease activity; it is 
possibly lowest in those with acute or newly identified disease. Yet it appeared to be higher 




prior to diagnosis, especially in younger patients(259, 260). Therefore, further investigation 
is required, including other possible components that may be involved such as vitamin D 
status (due to sun avoidance/supplementation)(261).  
MiR-320a was also implicated in inflammation, yielding a negative correlation with MCP-1. 
Furthermore, it was the only miRNA to be associated with fibromyalgia, a debilitating 
condition that will be discussed in chapter 6. Both miRNAs were predicted to target RUNX2 
and as such, their downregulation may support the progression of vascular calcification. 
Consequently, it was hypothesised that their downregulation results in a lack of 
cardioprotection, which was strengthened by identification of further targets such as 
beclin-1(262) and BMP receptor 1α(263). The opposite may also be true – that 
downregulation is cardioprotective – based on the predicted binding of beneficial targets 
such as SOCS1(264, 265), angiomotin-like protein 2(266), and PRCP(267, 268). Hence, it is 
clear that improved understanding of these two miRNAs is needed to formulate a theory 
of action.  
Indeed, for all of these miRNAs, the necessary next step is to probe functional effects in an 
in vitro cell model and confirm binding targets, in order to uncover their roles in SLE. It has 
become apparent that patients with SLE produce a distinct miRNA signature carried around 
their vasculature by EMVs. Within this signature, levels of individual miRNAs may be 
greater or smaller than in a healthy population and this holds huge promise for 
personalised medicine. For example, not only could an ‘SLE signature’ be used as a 
biomarker for improved diagnosis and monitoring, but novel therapeutics could also be 
designed to target the individual miRNAs.  
 
 
4.5. Chapter Summary 
Patients with SLE demonstrate differential expression of a number of vesicular miRNAs 
compared to healthy controls. This study considered a number of potential methods to 
measure miRNA abundance, and recognises that the identification of a housekeeping 




increased in association with increased inflammation and cardiovascular risk, and may be 
a protective mechanism through binding of harmful targets. Inversely, miR-93-5p is 
reduced in SLE, concordant with reduced cardioprotection. Both miR-30d-5p and miR-320a 
appeared to be downregulated, which is possibly a protective mechanism but further 
investigation is needed. The effects of this miRNA signature on endothelial function will be 
























SLE-Specific MiRNA Interrogation of Endothelial Cell Viability 
and Angiogenic Capacity 
 
 
5.1. Study Introduction 
This chapter describes the evidence in support of the SLE-linked miRNAs, identified in the 
screen described in chapter 4, as being related to endothelial cell viability and angiogenic 
capacity. To do so, HUVECs were used as an in vitro endothelial cell model, and were 
transduced with a lentiviral-GFP vector containing the miRNA of interest, as described in 
methods section 2.6. In this way, the effects of precise overexpression of individual miRNAs 
on HUVEC function could be elucidated. Cell viability/cytotoxicity was tested and a tube 
formation assay was used to model the effects of these miRNAs on angiogenesis. By 
performing such functional testing, it is possible to identify key pathways targeted by 
individual miRNAs, thus allowing further elucidation of their molecular targets and the 
mechanisms by which they link to symptomatic disease. Accordingly, this part of the study 
aimed to characterise the effects of miRNA overexpression on basic endothelial cell 
function and the objectives were as follows: 
 Generate individual lentiviral vectors that overexpress the five key miRNAs and use 
them to transduce HUVECs in order to test their function in cellular assays. 
 Determine the effect of miRNA overexpression on cell viability and migration 
capability. 







5.2. Chapter Methodology 
MiRNA overexpression constructs were generated as detailed in methods section 2.6; 
HUVECs were transduced with lentiviral vectors such that they overexpressed individual 
miRNAs, with successful integration confirmed by fluorescent microscopy and RT-qPCR 
(80% transduction efficiency). The effect of miRNA overexpression on HUVEC viability was 
then assessed using alamarBlue, on migration by scratch wound assay and on tube 
formation by Matrigel® assay, all of which are described in methods section 2.2. Effects of 
the miRNAs were further compared to control cells, which had been transduced with 





5.3.1. Overexpression of MiR-3148 and MiR-320a Increase Cell Viability 
Overexpression of both miR-3148 (p=0.020) and miR-320a (p=0.034) appeared to increase 
cell viability, as assessed by alamarBlue assays, when compared to control cells transduced 
with the empty pLL3.7 lentivirus (figure 5.1). None of the other miRNAs demonstrated a 






Figure 5.1: Cell viability of transduced HUVECs overexpressing miR-3148 or miR-320a. 
HUVECs were transduced with lentiviral vectors containing either miRNA constructs or the 
empty pLL3.7 plasmid at passage 3 (80% transduction efficiency) and cell viability was 
tested at passages 4-6.  Data shown represent absorbance at 570nm after 24 hours 
incubation with alamarBlue reagent. Analysis by independent samples t-test condensed 
into one graph. N=3 in triplicate. * denotes p≤0.05. 
 
 
5.3.2. MiRNA Overexpression Does Not Affect Scratch Migration 
Cell migration was assessed by HUVECs ability to close a scratch ‘wound’ bisecting a 
confluent monolayer, at time points of 0, 5 and 24 hours (figure 5.2). All scratches were 
fully closed at 24 hours, therefore rate of closure was assessed from 0-5 hours. However, 
overexpression of all miRNAs tested exerted no significant effects on migratory ability in 
the scratch model compared to control cells transduced with the empty pLL3.7 lentiviral 









Figure 5.2: Cell migration using a scratch assay. A scratch wound was created by drawing 
a p200 pipette tip vertically down a confluent well of HUVECs (p4-5) and representative 
micrographs are shown at 0, 5 and 24 hours. Cells had previously been transduced with 
either lentiviral vectors overexpressing the miRNs or the empty pLL3.7 control at passage 3, 





Figure 5.3: Rate of scratch closure over 5hrs. Scratch closure was analysed in HUVECs (p4-
5), which had been transduced with lentiviral vectors containing the five different miRNAs 
vs empty pLL3.7 vector at passage 3 (80% transduction efficiency). Analysis by one-way 










5.3.3. Overexpression of MiR-93-5p, MiR-320a and MiR-30d-5p Affects Tube Formation 
in Endothelial Cells 
A Matrigel®-based assay was utilised to model angiogenesis following miRNA 
overexpression by allowing measurement of angiogenic tube formation in vitro. A number 
of parameters were available to analyse, providing miRNA-specific data on angiogenic 
properties. Overexpression of both miR-93-5p and miR-320a significantly increased 
average tube length at 5 hours (p=0.038 and p=0.014 respectively), which was maintained 
at 24 hours (p=0.036 and p=0.035) compared to control cells transduced with empty pLL3.7 




Figure 5.4: Overexpression of miR-93-5p increases angiogenic tube length. Angiogenesis 
was tested using a Matrigel®-based tube formation assay, in HUVECs at p4-5, which had 
been transduced with either the control lentivirus (pLL3.7) or miR-93-5p lentivirus (80% 
transduction efficiency). Images were taken at 5 (A) and 24 hours (B) following plating. Tube 
length was measured using ImageJ software and statistical analysis using independent 







Figure 5.5: Overexpression of miR-320a increases angiogenic tube length. Angiogenesis 
was tested using a Matrigel®-based tube formation assay, in HUVECs at p4-5, which had 
been transduced with either the control lentivirus (pLL3.7) or miR-320a lentivirus (80% 
transduction efficiency). Images were taken at 5 (A) and 24 hours (B) following plating. 
Tube length was measured using ImageJ software and statistical analysis using 













Alternatively, while tube length was not affected, overexpression of miR-30d-5p yielded a 
significant decrease in numbers of angiogenic tubes at 5 hours (p=0.025; figure 5.6). 
However, this was not maintained at 24 hours (p=0.950, data not shown). Overexpression 





Figure 5.6: Overexpression of miR-30d-5p decreases angiogenic tube number. 
Angiogenesis was tested using a Matrigel®-based tube formation assay, in HUVECs at p4-
5, which had been transduced with either the control lentivirus (pLL3.7) or miR-30d-5p 
lentivirus (80% transduction efficiency). Tubes counted via ImageJ software and statistical 
analysis made by independent sample t-test. Scale bars represent 100μm. N=3 in triplicate. 















5.4.  Chapter Discussion 
 
5.4.1. The Effects of MiRNA Overexpression on Endothelial Cell Viability and Mobility 
The use of in vitro functional testing provides key evidence to the pathways underlying 
miRNA function, indicating areas of focus for individual miRNAs. To enable this, miRNA 
overexpression constructs were generated and packaged into lentiviral vectors, which were 
used to transduce cells such that they overexpressed individual miRNAs. Transduction was 
successful, with 80% efficiency and GFP expression that was stable for three passages. In 
this way, an in vitro endothelial model of miRNA overexpression was established, 
supporting the interrogation of miRNA effects on cell function. 
The first aspect of cell function to be tested was viability, primarily to ensure the miRNA 
overexpression constructs were not overtly damaging to the cells. This did not appear to 
be the case as none of the constructs resulted in a decrease in cell viability. Indeed, 
overexpression of both miR-3148 and miR-320a improved viability compared to controls, 
suggesting that overexpression of miR-3148 and miR-320a may increase cell proliferation 
or longevity, which may be validated in future studies.  
Assessing cell migration using a scratch technique did not yield any differences across the 
miRNAs tested, however, the lack of migratory effects allows refinement of target 
pathways of interest. This highlights the importance of testing different functional 
parameters when faced with an extensive list of potential targets.  
 
 
5.4.2. Assessing Angiogenesis in an Endothelial Model 
Angiogenesis is notoriously difficult to model accurately in vitro, with critics preferring in 
vivo studies for more representative results. Nevertheless, Matrigel®- based assays are a 
popular method for in vitro assays as the tube formation witnessed in these experiments 
provides an accurate simulation for the processes observed in vivo. The most common 
method is that used here, in which endothelial cells are plated on a layer of Matrigel®, yet 




these techniques may be more representative of a body system but they face more 
challenges than the standard method in terms of experimental set up and image 
analysis(269).  
Tube formation assays provide many parameters for analysis; in this study, it was decided 
to focus on tube number and length as images were analysed manually. Further parameters 
such as branch points can be analysed using image analysis software; this was attempted 
but was unsuccessful. It is interesting to note that in the two parameters assessed, miRNAs 
appear to stimulate different functional effects. Overexpression of miR-93-5p and miR-
320a increased tube length at 5 hours and was maintained at 24 hours;  this is not 
associated with increased tube number, which could reflect reduced network complexity 
and is typically detected in endothelial cells with advanced cellular age(270). However, 
intra-experimental cell passages were the same nor was cell viability reduced, indeed 
overexpression of miR-320a increased cell viability. One explanation of this is that miR-93-
5p and miR-320a target pathways associated with angiogenic sprouting, meaning tubes 
may continue to form but are unable to maintain branches. 
Network formation also appeared to be deleteriously affected with overexpression of miR-
30d-5p, resulting in reduced numbers of tubes. Unlike tube length, tube number has often 
been used as a marker of angiogenic capacity, with reductions representing impaired 
angiogenesis(271). Equal numbers of cells were plated and, as before, viability was 
unaffected, implicating angiogenesis as an area of interest for miR-30d-5p target analysis.   
This study has  identified key distinct differences in endothelial cells overexpressing 
different miRNAs, which will be critical in highlighting key pathways affected and thereafter 
progressing to target identification.  
 
 
5.5. Chapter Summary 
Lentiviral vectors were successfully generated, supporting overexpression of target miRNAs 
in an endothelial cell model. Overexpression of miR-3148 and miR-320a increased cell 




migration. Overexpression of miR-93-5p and miR-320a increased angiogenic tube length 
but not tube number, reducing network complexity, while overexpression of miR-30d-5p 
reduced tube number and thus implied reduced tube formation ability. Key targets affected 
by SLE-associated miRNAs may be implicated in angiogenesis although further investigation 
is needed to form a clear picture. The effects of miRNA overexpression on mitochondrial 
function and fatigue will next be discussed prior to later evaluation of the role of each 



























6.1. Study Introduction 
As discussed in chapter 1, fatigue is one of the most commonly reported symptoms of SLE, 
negatively affecting quality of life and presenting an unmet clinical need(52, 53). Improved 
understanding of the mechanisms underpinning fatigue in SLE would greatly contribute to 
better diagnosis and design of new therapies to improve this aspect of disease, which may 
also be applicable to other connective tissue disorders, such as fibromyalgia, promoting 
wellbeing in these patients. Following on from the cellular function tests described in 
chapter 5, SLE-specific miRNAs were analysed in relation to cellular respiration and 
associations with clinical fatigue data in an SLE population. It was hypothesised that SLE-
specific miRNAs alter mitochondrial function and are associated with symptoms of fatigue, 
and the objectives were as follows: 
 Establish the level of fatigue experienced by controls and patients with SLE. 
 Correlate miRNA levels and patient data with clinical fatigue and quality of life 
scores. 
 Determine miRNA associations with self-reported incidence of musculoskeletal 
symptoms. 








6.2. Chapter Methodology 
This study utilised the same patient cohort as that described in chapter 4 (14 controls and 
25 patients with SLE). Motor and cognitive fatigue levels of the whole cohort were assessed 
using the FSMC questionnaire, and quality of life scores were recorded, all as detailed in 
2.7.2. BILAG scores were also obtained during patient recruitment, although ACR criteria 
were favoured for analysis in previous chapters; musculoskeletal involvement was 
recorded during the BILAG assessment, the data of which were used in this study. As per 
BILAG guidelines, ‘musculoskeletal involvement’ includes myositis, arthritis, tendonitis, 
tenosynovitis, arthralgia and myalgia (272). Finally, HUVECs were transduced with lentiviral 
vectors to overexpress the specific miRNAs, as in chapter 5, to interrogate their effects on 
cellular respiration using Seahorse Cell Mito Stress assays and gene ontology; more details 





6.3.1. Fatigue Scores are Elevated in SLE, and are Associated with Inflammation and 
MiRNA Abundance 
When analysing fatigue across the cohort, the FSMC questionnaire was separated into 
motor and cognitive fatigue arms to provide the most specific data; higher scores indicated 
greater levels of fatigue. Nevertheless, patients with SLE demonstrated significantly greater 
fatigue scores across all arms compared to controls (p<0.001; figure 6.1), regardless of 
disease activity (stable and flare all p<0.001). There were no differences in patients with 






Figure 6.1: Fatigue scores in patients and controls. Motor (A), cognitive (B) and total 
fatigue (C) scores were calculated using the FSMC questionnaire. Comparisons between 
controls and all patients were assessed by Mann-Whitney U test, and between controls and 
disease activity (stable and flare) by Kruskal-Wallis test. Error bars represent SEM. Control 





Motor and cognitive fatigue scores correlated positively with EMV number (p=0.001) and 
QRISK scores (p<0.02), as well as IL-6 (p<0.05) and BLyS (p<0.02) across the whole cohort 
of participants (table 6.1). Singularly, motor fatigue scores correlated with MCP-1 (p=0.041) 
and PWV (p=0.009), whereas cognitive fatigue scores correlated with VEGF (p=0.044). 
Furthermore, motor fatigue scores were elevated in participants with fibromyalgia 
(p=0.034), while cognitive fatigue were highest in participants with a positive family history 
of hypertension (p=0.024). Finally, miR-3148 abundance was positively associated with 
fatigue scores (p<0.05) whereas miR-30d-5p and miR-320a abundance relative to let-7a 
































































































































39.3 ± 10.8 
25.9 ± 11.2 
p=0.034 
38.0 ± 11.5 
25.3 ± 10.8 
p=0.065 
77.3 ± 22.3 








32.5 ± 9.1 
25.2 ± 13.1 
p=0.069 
31.9 ± 8.5 
24.2 ± 12.5 
p=0.024 
64.4 ± 17.2 
49.4 ± 25.5 
p=0.022 
 
Table 6.1: Correlations between FSMC scores, clinical data and miRNA abundance in total 
cohort. Data shows the whole cohort (control n=14, SLE n=25), with separate comparisons 
according to FSMC motor, cognition and total scores. Upper section presents Spearman’s 
rho correlation coefficients; lower section presents mean score (± standard deviation) with 




Within the patient cohort, both motor and cognitive fatigue correlated positively with VEGF 
levels (p<0.015; table 6.2). Motor fatigue alone correlated with total ACR score, lymphocyte 
number and C3 levels (p<0.05), however both fatigue arms correlated with miR-93-5p 
abundance per MV (p<0.05) and cognitive fatigue was further associated with miR-30d-5p 
abundance per MV (p=0.048). Additionally, fatigue scores were elevated in patients 
experiencing oral ulcers and those with a family history of high cholesterol levels (p<0.03) 
but were lowest in patients with reduced C4 and those with persistent migraines (p<0.05).  
 













































    






39.2 ± 8.0 
28.3 ± 6.8 
p=0.003 
37.1 ± 8.9 
28.2 ± 6.6 
p=0.029 
76.3 ± 16.7 






23.8 ± 2.5 
37.1 ± 8.7 
p=0.028 
22.0 ± 3.3 
36.1 ± 8.2 
p=0.003 
45.8 ± 4.3 
73.2 ± 16.6 
p=0.006 






39.8 ± 5.8 
29.8 ± 9.8 
p=0.019 
37.8 ± 6.8 
29.6 ± 9.5 
p=0.019 
77.6 ± 12.4 






27.0 ± 8.7 
36.5 ± 8.8 
p=0.113 
23.5 ± 6.2 
35.9 ± 8.3 
p=0.019 
50.5 ± 14.8 







Table 6.2: Correlations between FSMC scores, clinical data and miRNA abundance in 
patient cohort. Data are shown with separate comparisons according to FSMC motor, 
cognition and total scores. Upper section presents Spearman’s rho correlation coefficients; 
lower section presents mean score (± standard deviation) with statistical analysis using 
Mann-Whitney U test. N=25. 
 
 
6.3.2. LQOL Scores are Associated with Markers of Disease as well as Prescribed 
Medications in SLE 
Quality of life in patients with SLE was assessed using the LQOL score, which correlated 
negatively with both VEGF and C3 levels (p<0.04; table 6.3). Quality of life was also lowest 
in patients with oral ulcers, photosensitivity and those prescribed atypical 
immunosuppressives (in this case tacrolimus and/or rituximab; p<0.04). On the other hand, 
quality of life scores were highest in patients with low C4 and those prescribed 
acetylcholinesterase (ACE) inhibitors (p<0.04). 
 





    
ACR Criteria: Oral Ulcers Present (n=16) 
Absent 
34.77 ± 26.32 






42.19 ± 28.56 
78.75 ± 14.03 
p=0.019 
Low C4 Present (n=12) 
Absent 
59.38 ± 28.81 
40.38 ± 28.34 
p=0.037 
ACE Inhibitors Present (n=3) 
Absent 
87.50 ± 8.84 






12.50 ± 13.50 






Table 6.3: Associations between LQOL and clinical data in patients with SLE. Upper section 
represents data analysed by Spearman’s Rank Correlation Coefficient and lower section 




6.3.3. MiR-126-3p and MiR-93-5p are Increased in Patients with Musculoskeletal 
Symptoms 
Two of the miRNAs analysed demonstrated associations with self-reported musculoskeletal 
symptoms in patients with SLE, namely miR-126-3p and miR-93-5p (figure 6.2). Both 
miRNAs were elevated in patients reporting musculoskeletal symptoms compared to those 
without (p=0.035 and p=0.008 respectively). Furthermore, abundance of miR-93-5p per 
microvesicle was also significantly higher in patients with musculoskeletal symptoms 
(p=0.009); abundance of miR-126-3p per microvesicle demonstrated a trend towards an 
elevation but was not significant (p=0.056). No other miRNAs tested demonstrated any 







Figure 6.2: The presence of miRNAs alongside musculoskeletal involvement in SLE. 
Abundance of miR-126-3p per ml of plasma (A) and per microvesicle (B) was quantified in 
patients with/without musculoskeletal symptoms, as was abundance of miR-93-5p per ml 
of plasma (C) and per microvesicle (D). Musculoskeletal symptoms were classed as a BILAG 
score of C or above (mild to severe symptoms at present time). Analysis was performed 
using Mann-Whitney U test and SEM. Musculoskeletal symptoms present in 9 patients, 










6.3.4. Overexpression of MiR-126-3p and MiR-93-5p May Impact Cellular Respiration 
Seahorse bioanalysis was performed to assess the effects of miRNA overexpression on 
cellular respiration. MiR-126-3p demonstrated a striking effect (figure 6.3), with increased 
basal ECAR (p=0.028) and trends towards increased maximal ECAR (p=0.061) and OCR 
(p=0.372) compared to cells transduced with the control lentivirus (pLL3.7). No difference 
in basal OCR was evident (p=0.969). Similar trends were observed with miR-93-5p, although 
an n=2 prevented complete statistical analysis. Thus, overexpression of both miRNAs 
yielded respiratory profiles that were more glycolytic than controls. No significant 
differences in respiratory effects were detected with the overexpression of the three other 







Figure 6.3: Seahorse bioanalysis of respiration in cells overexpressing miRNAs. HUVECs at 
p3 were transduced with either lentiviral vectors containing either a miRNA overexpression 
construct or with a control empty pLL3.7 lentivirus at 80% transduction efficiency. Seahorse 
bioanalysis was performed using Seahorse Xfp Cell Mito Stress Test, with HUVECs plated at 
p5-7. Basal OCR (A), maximal OCR (B), basal ECAR (C) and maximal ECAR (D) were recorded, 
providing a profile of cellular respiration (E). Statistical analysis was performed using 






To identify potential targets for future work, gene ontology was again performed for miR-
126-3p, in this case using ‘cellular respiration’ as a search term. Targets that were also 
predicted for miRNAs producing no effect during Seahorse bioanalysis were removed, 
producing the shortlist below (table 6.4). Cytoscape rankings were unavailable for these 
data, nor is miR-93-5p data described due to the lack of understanding and predicted 
targets available for that miRNA. 
 












6.4. Chapter Discussion 
 
6.4.1. Fatigue and Quality of Life in SLE 
Within the 2014 LUPUS UK study introduced in chapter 1, of 2299 patients with SLE, 91% 
reported fatigue/weakness(52). Another LUPUS UK study revealed that fatigue was a major 
contributing factor preventing patients with SLE from maintaining stable employment; of 
the 399 patients interviewed, 40.45% had left employment due to their disease(273). 
Cognitive function is also somewhat impaired in SLE, with patients unable to maintain 
sustained attention for as long a period of time as controls(274, 275). The pathological 
mechanisms underlying fatigue and cognition in SLE are not yet fully understood, although 
some structural differences have been noted in brain scans of patients with SLE such as 
larger perivascular spaces and alterations in the caudate(275).  
Assessment of fatigue in SLE presents challenges due to the subjective nature of the data; 




in use, with one of the most common being the Fatigue Severity Scale(274). The scales 
utilised in this study were the FSMC and the LQOL, assessing cognitive and motor fatigue, 
and patient quality of life. The FSMC tool is most often used in cases of multiple sclerosis, 
although it is also relevant to SLE(184, 275). In this case, the FSMC was applied rather than 
the more general Fatigue Severity Scale as it was found to be more comprehensive, 
providing feedback on both cognitive and motor aspects of fatigue. The lack of a consensus 
on measurements of fatigue, which are subjective in themselves, highlights a knowledge 
gap and the potential for consideration of biomarkers as an objective measure of fatigue 
levels across patients. Quality of life was also assessed to provide additional data on the 
extent to which SLE affects not only fatigue, but also critical inter- and intrapersonal 
measures.  
When studying fatigue, patients with SLE were found to have higher FSMC scores than 
controls, supporting previously published data. Scores were also increased in patients with 
fibromyalgia compared to the rest of the population (controls and patients without 
fibromyalgia). Again, this is unsurprising as fibromyalgia is another condition characterised 
by excessive fatigue(276), although these data serve to demonstrate the unmet clinical 
need for improved recognition of fatigue in these poorly understood diseases.  
FSMC scores were able to differentiate between patients and controls using a number of 
markers. Previous reports have concluded that fatigue does not correlate with disease 
activity in SLE(274), therefore it is interesting to note the associations with markers of 
inflammation in this study. The roles of MCP-1, IL-6 and BLyS in SLE have been discussed in 
previous chapters, and while it is true that they are not representative of disease activity 
per se, fatigue is a common symptom across inflammatory disease(277). Indeed, elevated 
IL-6 has already been linked to impaired cognitive function in SLE(278) and to fatigue 
measures in rheumatoid arthritis(277, 279). Cardiovascular factors also correlated with 
FSMC score; as discussed in chapters 1 and 3, inflammation and cardiovascular disease are 
interlinked in SLE and the connection between fatigue and cardiovascular measures could 
be reflective of this. Interestingly, CD144+ EMVs showed a strong positive correlation with 
FSMC within the whole cohort; again, this could reflect the increased inflammation and 
endothelial dysfunction, but it also reintroduces the potential for EMVs to act as 




Another potential biomarker identified in this study is miR-3148, which correlated 
positively with fatigue score across the cohort. Chapter 4 described an increase of miR-
3148 in SLE yet so little is known about this miRNA that it is difficult to hypothesise whether 
miR-3148 directly affects fatigue symptoms or is solely a biomarker of underlying disease, 
a question that necessitates further study. Additionally, the associations between miR-
320a and miR-30d-5p and motor fatigue were only present when analysing the miRNAs 
relative to let-7a, again supporting the use of more detailed miRNA housekeeper-based 
analysis.  
The distinction between motor and cognitive branches of the FSMC allowed identification 
of separate pathways for future analysis, such as the link between a family history of 
hypertension and cognitive fatigue. It is interesting to note that the presence of 
hypertension was not significantly associated but the risk of its development was; a similar 
finding has been detected in young adults with sleep deprivation, and microvascular 
changes associated with endothelial dysfunction and hypertension have been known to 
result in cognitive impairment(280-282). The role of SLE vascular function in cognition will 
be further considered in the final chapter. 
Within the patient only cohort, FSMC score correlated with ACR score, bringing into 
question the ability of fatigue scores to reflect disease activity, an area which evidently 
requires further refinement. It also correlated with lymphocyte number, VEGF and C3, 
reinforcing the association between markers of inflammation and fatigue symptoms. 
Furthermore, increased levels of VEGF could begin to explain the higher incidence of oral 
ulcers in patients with fatigue, as the VEGF pathway has been previously linked to mucosal 
ulceration in SLE(283). Oral ulceration is a factor in the ACR diagnostic criteria for SLE, thus 
its association with fatigue could be as a result of a disease flare; alternatively the presence 
of fatigue could have triggered or exacerbated ulceration(284). On the other hand, low 
levels of C4 was associated with reduced fatigue, which has already been noted in cases of 
chronic fatigue syndrome(285).  Intriguingly, fatigue was increased in patients with a 
positive family history of hypercholesterolaemia but yielded no connection to patient lipid 
levels or statin use – the role of genetics in diseases characterised by high fatigue levels 
would be an interesting area for further study. As with hypertension, familial 
hypercholesterolaemia has been associated with cognitive impairment, most likely through 




and may indicate structural differences in the brain that could contribute to fatigue(275, 
288). 
Regarding miRNAs as biomarkers, miR-93-5p correlated with measures of fatigue in 
patients with SLE, which may be related to its associations with musculoskeletal symptoms, 
as discussed below. MiR-30d-5p abundance was also associated with cognitive fatigue in 
SLE; the role of miRNAs in cognitive function is a fascinating area that will be considered in 
the proceeding future work section. 
As with fatigue, reduced quality of life was associated with inflammation and disease 
activity (VEGF, C3, C4, oral ulcers and photosensitivity). Although the n numbers were 
small, quality of life appeared to be highest in patients taking ACE inhibitors and lowest in 
those taking non-standard immunosuppressives. This may reflect better disease 
management and symptomatic relief in patients taking typical medication as opposed to 
those needing stronger treatments. 
 
 
6.4.2. The Role of MiRNAs in Musculoskeletal Symptoms in SLE 
The next stage of this project utilised the BILAG data recorded at the time of patient 
recruitment, particularly the reporting of musculoskeletal symptoms. It became apparent 
that both miR-126-3p and miR-93-5p were increased in the circulation of patients reporting 
musculoskeletal involvement, which is striking as these miRNAs were also shown to perturb 
mitochondrial function in vitro. It appears obvious that if energy production is impaired, 
patients may experience fatigue, particularly motor fatigue or muscular weakness, as 
muscle tissue is mitochondria-dense(289). Impairments in mitophagy or mitochondrial 
function are present in myopathic diseases, including the autoimmune disease 
dermatomyositis, which shares with SLE a high involvement of type 1 IFNs and ROS(289, 
290). However, it is clear that the two miRNAs must play different roles in fatigue in SLE as 
they follow opposite expression patterns and have different predicted targets. miR-126-3p 
is increased in SLE and thus any induced mitochondrial dysfunction may then contribute to 
the musculoskeletal symptoms. Alternatively, the overexpression of miR-126-3p could be 




downregulation of miR-93-5p in SLE is protective. This is supported by the trend towards in 
vitro mitochondrial dysfunction combined with the increased musculoskeletal symptoms 
in patients with higher levels. Identification of the mitochondrial targets of miR-126-3p and 
miR-93-5p, as described earlier, would assist in identification of the pathological pathways 
underlying mitochondrial dysfunction and fatigue in SLE. Additional studies could focus on 
physiological testing of muscle function in patients to further differentiate symptoms, 
characterise cellular changes and relate this to miRNA function. 
 
 
6.4.3. Do MiRNAs Protect or Damage Mitochondria in SLE? 
Seahorse bioanalysis provides data on oxygen consumption and extracellular acidification 
rates, which respectively represent mitochondrial respiration and glycolysis, allowing 
detailed analysis of cellular energy metabolism. Unfortunately, OCR measurements were 
highly variable, particularly in control wells, and only an n=2 was available for miR-93-5p 
thus preventing statistical analysis. Nevertheless, this technique identified differences in 
energy profiles between HUVECs overexpressing miR-126-3p and controls, specifically an 
increase in ECAR when overexpressing the miRNA. Thus, when comparing respiratory 
profiles, cells overexpressing miR-126-3p appeared to favour more glycolytic pathways, 
potentially indicating a mitochondrial defect. In recent years, numerous groups have begun 
to consider cellular respiration in SLE, often focusing on leukocytes. The high incidence of 
inflammation and ROS accumulation, combined with disease-specific impairments in 
mitophagy and clearance of debris appears to reduce mitochondrial efficiency, which may 
warrant a switch towards glycolytic ATP production(291-293). 
Gene ontology identified a number of potential miR-126-3p targets involved in cellular 
respiration, with unique targets being frataxin, dihydrolipoamide s-acetyltransferase and 
subunits of NADH:ubiquinone oxidoreductase and cytochrome c oxidase. Of these, all are 
found within the mitochondria (data from OMIM online catalogue of human genes) and 
have critical roles in respiration, which may lead to poor mitochondrial function when 
perturbed, for example reductions in frataxin or cytochrome c oxidase result in increased 




impairments could then result in fatigue symptoms; these links between miRNAs and 
fatigue symptoms have not yet been characterised, presenting fascinating new avenues for 
further study.  
 
6.5. Chapter Summary 
MiR-126-3p and miR-93-5p appear to increase glycolytic respiration in vitro, implying 
functional responses to mitochondrial dysfunction; they are also associated with 
musculoskeletal symptoms in patients with SLE, potentially presenting a link between 
cellular respiration and motor fatigue in this disease. Fatigue is indeed increased in patients 
with SLE, and is associated with markers of inflammation and cardiovascular disease. 
MiRNAs are also positively associated with fatigue levels, demonstrating potential as novel 



























7.1.1. AIM 1: Identification of Novel Biomarkers for Cardiovascular Risk in SLE 
It is now clear that patients with SLE demonstrate increased levels of inflammatory and 
cardiovascular risk markers, which moves towards explaining the accelerated 
atherosclerosis, endothelial dysfunction and cardiovascular risk introduced in chapter 1. It 
is vital that this increased risk is recognised in order to prevent premature mortality and 
support patient wellbeing, however CVD risk algorithms differ in accuracy when compared 
to each other and also when used in different populations(114, 115). The discordance in 
risk score in SLE can be abrogated by inclusion of SLE factors(123, 296); indeed, this body 
of work identified a significant cohort of patients that had been missed by the current 
system. Missed patients were found to have higher levels of inflammation and 
cardiovascular factors, thus it can be construed that the QRISK3 algorithm is more 
representative of cardiovascular risk in SLE than its predecessors. It may be argued that this 
is obvious, as other algorithms do not include SLE as a factor, yet this only strengthens the 
argument of using QRISK3 to predict SLE cardiovascular risk. Nevertheless, the design of 
cardiovascular algorithms for risk prediction must also be questioned – can one algorithm 
reflect all intrapersonal differences and should one global algorithm be used? With the 




universal calculation that applies to all, however the combination of prediction algorithms 
and biomarker panels shows great potential for personalised medicine.  
In a recent publication, Felten et al. list the identification of relevant biomarkers for 
individualised treatment as one of the top 10 biggest challenges faced when managing 
SLE(297). Although biomarker panels consisting of circulating factors such as cytokines are 
under investigation by other groups(298), this research focused on EMVs as novel 
biomarkers for cardiovascular risk. Their use as such was supported by their associations 
with QRISK3 and other markers of cardiovascular and inflammatory disease. Furthermore, 
by being released directly from the endothelium, they more accurately reflect endothelial 
involvement than a panel of systemic cytokines would. Isolation and quantification of 
microvesicles is also relatively simple following protocol optimisation, and can be 
performed from a small volume of peripheral blood using only a centrifuge and a flow 
cytometer. Thus, EMVs provide promising alternatives to lengthy and complex biomarker 
panels for future characterisation of cardiovascular risk. 
 
 
7.1.2. AIM 2: Determination of a Vesicular MiRNA Signature in Patient Plasma 
Personalised medicine may be the key to management of heterogeneous diseases such as 
SLE and this was one reason why the contents of EMVs were probed in patients vs controls; 
another reason was that interrogation of functional effects may reveal mechanisms and 
novel targets for future therapies. MiRNAs were chosen over other contents due to their 
bioactivity and relative novelty, with their effects in SLE still uncharacterised.  
Many studies have aimed to quantify miRNA abundance in CVDs and in SLE but a consensus 
panel is still lacking, with studies presenting conflicting results obtained from various 
different bodily fluids and cellular origins. This research study took a more measured 
approach, identifying key miRNAs through a bioinformatics workflow and analysing this 
core panel in the microvesicular fraction of plasma. The miRNAs were correlated with 
clinical measurements, in line with their potential use as biomarkers, before gene ontology 




to emerge, a snapshot of the complex interactions between vesicular miRNAs and the 
endothelium in SLE. Ideally, one miRNA would have been identified as a definitive 
biomarker and leading area of future research; however, the data proved to be more 
complex, indicating a number of potential molecular mechanisms and avenues for future 
study. This complexity reflects the numerous clinical symptoms observed in SLE  and 
highlights the need for a more detailed understanding of their interaction, supporting a 
personalised medicine strategy to diagnose and treat SLE.   
 
 
7.1.3. AIM 3: Elucidation of Functional Effects of SLE-Related MiRNAs in Endothelial Cells 
Potential roles for each miRNA in the SLE panel were interrogated by combining the data 
produced in chapters 4-6. To do so, overexpression of each miRNA was modelled in vitro 
using lentiviral vectors in endothelial cells. These vectors are one of the most commonly 
used methods for investigating miRNA overexpression since they integrate into the 
genome of cells, thus maintaining higher and more prolonged levels of expression than 
more traditional methods such as miRNA mimics(299, 300). A number of in vitro tests 
followed, designed to assess endothelial cell function across a range of parameters to 
further characterise miRNA function, as discussed below. 
 
 
7.1.3.1  The Role of MiR-126-3p in SLE 
MiR-126-3p was elevated in patients experiencing a disease flare but this was not the case 
in stable patients, suggesting a possible link with disease activity, which was supported by 
correlations with the QRISK scores, EMV number, renal disorder and the use of 
immunosuppressives. A range of potential targets were identified, yet overexpression in 
endothelial cells produced an effect only when analysing cellular respiration where it 
induced a glycolytic shift. Thus, potential targets involved in mitochondrial function are of 
the most interest, such as frataxin and cytochrome c oxidase. Similar results have been 




SLE is highly novel. If the overabundance of miR-126-3p in SLE flares did contribute to 
mitochondrial dysfunction, this may begin to explain the overabundance in patients with 
musculoskeletal symptoms such as myalgia, otherwise this finding may simply be utilised 
to further support the concept of miR-126-3p as an indicator of increased disease activity. 
Either way, its associations with SLE disease activity are striking and analysis of its 
mitochondrial targets and effects on other cell types will help to elucidate whether its 




7.1.3.2  The Role of MiR-3148 in SLE 
Very little was known regarding miR-3148 prior to this research, which found it to be 
increased in SLE and associated with cardiovascular risk. In lentiviral vector miR-3148 
overexpression studies, although the levels of transduction efficiency were the same as for 
other miRNA containing lentiviral vectors, miR-3148 was not produced at the same high 
levels, suggesting that it is not expressed readily in endothelial cells or that levels were 
simply too low for accurate quantification. MiR-3148 correlated positively with FSMC 
levels, which may support its use as a biomarker for fatigue/disease activity, yet had no 
effect on HUVECs in terms of tube formation or mitochondrial function, but had a positive 
effect on viability, which necessitates further study. Many of its predicted targets were 
associated with vascular calcification, such as RUNX2. Indeed, unpublished work by our 
group has recently demonstrated that overexpression of miR-3148 resulted in decreased 
calcification of vascular smooth muscle cells in vitro, alongside reduced RUNX2 abundance, 
and is under further investigation. Thus, it may be that this miRNA plays a greater role in 
vascular smooth muscle cells, where it may offer vasculoprotection in SLE.  
 
 




Unlike miR-3148, miR-93-5p appeared to be more active in the studies presented, with 
overexpression in HUVECs resulting in impaired tube formation and a trend towards a 
glycolytic shift. The concurrent reduction in miR-93-5p abundance in patients with SLE thus 
suggests a protective mechanism, designed to prevent the destructive properties of this 
miRNA when it is overly abundant. It is interesting to consider the negative correlations 
with microvesicles, neutrophils and MCP-1, reinforcing the theory that this miRNA is 
purposefully downregulated in periods of inflammation. The increased abundance of miR-
93-5p in patients with musculoskeletal symptoms and positive correlation with FSMC score 
supports the notion of this miRNA as damaging yet further study is needed to elucidate its 
potential role in fatigue.  
 
 
7.1.3.4  The Role of MiR-320a in SLE 
The abundance of miR-320a appeared to demonstrate a contrasting pattern in 
microvesicles generated in vitro compared to those isolated from patient plasma, 
emphasising the difference between cellular and human models. However, abundance in 
patients was only significantly lower than controls when expressed per microvesicle, 
therefore it is possible that more miR-320a is shuttled into microvesicles (as in vitro) but 
the increased number of vesicles masks this. Overexpression appeared to increase cell 
viability but also impaired tube formation. Furthermore, abundance was associated with 
incidence of fibromyalgia and FSMC score. Thus, the role of miR-320a appears complex and 
unclear; abundance per microvesicle may be reduced but if more microvesicles contain 
miR-320a and consequently interact with cells, this may lead to deleterious effects e.g. 
impaired angiogenesis and fatigue. Pathway and mechanistic analysis will enable further 
characterisation of the role of this miRNA, as discussed in 7.3. 
 
 




The final miRNA to be studied was miR-30d-5p, which was reduced in SLE concurrent with 
disease activity, as indicated by negative correlations with EMV number, white blood cells 
and disease duration. A range of potential targets were identified and it is possible that this 
miRNA demonstrates pleiotrophic effects as overexpression reduced angiogenic tube 
number while plasma abundance was associated with fatigue. As with miR-93-5p, the 
reduction in SLE may be a protective mechanism, preventing angiogenic impairments. It is 
therefore interesting to note the positive correlation between reduced abundance per 
microvesicle and low cognitive fatigue score, and to determine in future work whether 
overabundance of miR-30d-5p is detrimental to pathways involved in cognition. Summary 
table 7.1. highlights the key findings generated by our laboratory regarding miRNA activity 
in SLE, which will be used to design future experiments. 
 
MiRNA Abundance in SLE Key Effects of Overexpression In Vitro 
MiR-126-3p Increased in flares Glycolytic shift in HUVECs 
MiR-3148 Increased in SLE Decreased calcification of VSMCs and 
reduced RUNX2 abundance 
MiR-93-5p Reduced in SLE Reduced angiogenic tube length and 
trend towards glycolytic shift in 
HUVECs 
MiR-320a Reduced in SLE Reduced angiogenic tube length and 
increased viability in HUVECs 
MiR-30d-5p Reduced in SLE Reduced angiogenic tube number 
 
Table 7.1. MiRNA summary table. This table highlights key findings from our group 
regarding miRNA abundance in SLE and the effects of miRNA overexpression on in vitro cells 




7.2. Limitations and Considerations 
While this research has been successful in achieving its aims, a review of its limitations and 




When studying the SLE and control cohorts, a larger population size would ensure greater 
representation and more accurate statistical analysis. In this instance, patient population 
size was limited due to availability – many patients treated at the Kellgren Centre for 
Rheumatology were already enrolled in other research studies such as drug trials, and were 
therefore unavailable. However, this was not deemed to limit interpretation of results as 
similar studies with smaller population sizes have previously been published(157, 158). 
Longitudinal studies would also be very interesting when considering the changes in EMV 
number, miRNA abundance and cardiovascular risk over time, but this was not feasible 
during the current project.  
The research in question focused on EMVs yet microvesicles can be isolated from a number 
of cell types, therefore it would be interesting to consider circulating microvesicles of other 
origins, such as PMVs. These were discussed in chapter 4 but could also be probed for 
miRNAs in further work. Another factor to consider is the number and miRNA content of 
circulating exosomes, which were removed in this project, yet could enhance 
understanding of the SLE miRNA profile. Furthermore, although the methods for EMV 
isolation and quantification used in this work have been validated elsewhere, a consensus 
on EMV characterisation, as well as the preceeding considerations, must be determined 
before biomarker technology featuring EMVs can be developed. Such technology would 
ideally be quick, cheap and preferably automated to enable rapid patient stratification in a 
busy clinical environment; establishment of a further research project to address these 
issues is thus recommended prior to clinical use. 
Difficulties arose when comparing miRNA abundance, firstly when optimising 
quantification from plasma samples and in vitro, which could be improved through 
development of a method to detect miRNAs at low abundance. A measured approach for 
selecting and quantifying miRNAs by qPCR was taken for this project, although it would also 
be possible to perform a larger scale screen followed by production of a shortlist based on 
the levels of miRNAs identified in the samples. It is worth noting that next generation 
sequencing was attempted early in the project but was unsuccessful due to the low 
abundance of RNA isolated from microvesicle samples as only 1ml of total plasma was 
available in this cohort for analysis. Furthermore, a defined method of analysing miRNA 




ensure accurate quantification, the identification of a ‘housekeeper’ miRNA would greatly 
enhance analysis based on human samples or between different conditions in vitro.  
The final limitations pertain to functional analysis of miRNA activity in vitro. This research 
characterised the effects of miRNA overexpression on endothelial cells, however 
supplementing this with an underexpression model would further refine and support the 
conclusions drawn. Indeed, miRNA sponges were generated(302) but were discontinued 
due to a lack of efficacy. Other alternatives include antagomiRs(303) or gene knockouts, 
which will be considered in 7.3. Lastly, the functional tests employed in this project were 
selected to represent a range of cellular processes integral to endothelial function during 
basal conditions. Nevertheless, additional tests such as NO measurements or endothelial 
function in response to inflammatory treatment would provide further detail and act as an 
in vitro model of the endothelium in an inflammatory disease such as SLE. N numbers in 








7.3. Future Directions 
This work offers many avenues for further study, starting with the development of miRNA 
silencing models to characterise the functional effects of miRNA underexpression in vitro. 
Following this, pathway and target analysis will be necessary for elucidation of the 
mechanisms identified during the functional testing. To do so, transcriptome analysis will 
be combined with pathway recognition software to identify key processes affected by the 
miRNAs. Individual targets can also be confirmed using, for example, luciferase reporter 




production(304); a luciferase reporter construct was attempted during the course of this 
project, but was unsuccessful.  
An emerging area of particular interest is the role of EMVs and miRNAs in fatigue in SLE, as 
introduced in this project through correlations with fatigue scores and functional effects 
on cellular respiration. This could separate into two branches, studying motor fatigue 
through e.g. muscle testing, or cognitive function, which has been highlighted numerous 
times in this thesis as a major unmet need in SLE. When studying fatigue and cognitive 
function in SLE, the blood brain barrier (BBB) is a fascinating interface between the vascular 
endothelium and the nervous system, having already been associated with fatigue and 
impaired cognition in inflammatory diseases such as SLE(305-307). Therefore, full 
characterisation of the effects of the SLE environment on the BBB, including EMV trafficking 
and miRNA functions would shed light on an ongoing and underresearched area, providing 
novel avenues for therapeutic research. 
The overarching aim of this project was to establish whether EMVs can be added to the 
armament of risk factors used for identifying patients with SLE at elevated risk of future 
cardiovascular events. By combining EMV levels with risk algorithms and miRNA 
abundance, the development of more a comprehensive stratification tool will support 
identification of future patients with high cardiovascular risk. One way to do this in future 
studies would be to utilise an artificial intelligence approach to provide personalised 
reports relevant to each patient and acknowledge the heterogeneous nature of SLE. In 
doing so, patients with SLE will be able to receive tailored treatment and monitoring plans, 
preventing premature mortality and improving quality of life. 
7.4. Concluding Statements 
Patients with SLE demonstrate increased levels of inflammation and cardiovascular risk, 
which is represented by the QRISK3 algorithm and by circulating numbers of EMVs. A 
distinct miRNA signature is present in the vesicular fraction of patient plasma, with 
individual miRNAs associated with measures of inflammation and cardiovascular risk. In 
vitro functional testing has characterised the effects of individual miRNA overexpression 




To conclude, EMVs demonstrate great potential for use as biomarkers of cardiovascular 
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i. Effects of MiRNA Overexpression on Cell Viability 
As described in chapter 5, only HUVECs transduced with miR-3148 and miR-320a lentiviral 
vectors demonstrated increased cell viability (app. figure i.; indicated by dashed line, 
significance only when analysed by t test as in chapter 5). No other miRNAs yielded 
significant differences when analysed by ANOVA or t-test (126-3p p=0.898; 93-5p p=0.735; 






App. Figure i. Effects of miRNA overexpression on cell viability. HUVECs were transduced 
with either miRNA lentiviral vectors or the control pLL3.7 lentivirus at passage 3 (80% 
transduction efficiency) and cell viability was tested at passages 4-6.  Data shown represent 
absorbance at 570nm after 24 hours incubation with alamarBlue reagent. Analysis by one-
way ANOVA and independent samples t-test. N=3 in triplicate. * denotes p≤0.05.  
 
ii. Effects of MiR-126-3p and MiR-3148 on Tube Formation 
Chapter 5 highlighted the differences in tube length and number when HUVECs 
overexpressed miR-93-5p, miR-320a or miR-30d-5p, which have been highlighted with a 
dashed line in app. figure ii. Neither miR-93-5p nor miR-320a affected tube number at 5 
hours (p=0.073 and p=0.104) or at 24 hours (p=0.607 and p=0.664). On the other hand, 
overexpression of miR-30d-5p had no effect on tube length at either 5 hours (p=0.085) or 
at 24 hours (p=0.268). Transduction with miR-126-3p lentivirus produced no significant 
effect on tube length (5hrs p=0.160, 24hrs p=0.120) or number (5hrs p=0.175; 24hrs 
p=0.707) compared to control and neither did miR-3148 (tube length 5hrs p=0.091; 24 hrs 
p=0.475; tube number 5hrs p= 0.549; 24hrs p=0.381). These statistics reflect independent 






App. Figure ii. Tube formation in HUVECs overexpressing miRNAs. Angiogenesis was 
tested using a Matrigel®-based tube formation assay, in HUVECs at p4-5, which had been 
transduced with either the control pLL3.7 lentivirus or miRNA lentivirus (80% transduction 
efficiency). Images were taken at 5 (A) and 24 hours (B) following plating. Tube formation 
was measured using ImageJ software and statistical analysis using one way ANOVA and 
independent samples t-test. N=3 in triplicate. * denotes p≤0.05. 
iii. MiRNA Abundance in Patients with Musculoskeletal Symptoms 
As described in chapter 6, patients experiencing musculoskeletal symptoms were also 
found to have increased abundance of miR-126-3p and miR-93-5p. This was not the case 
with any of the other miRNAs tested (app. table i.). 
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App. Table i. MiRNA abundance in patients with musculoskeletal symptoms.  
Musculoskeletal symptoms were classed as a BILAG score of C or above (mild to severe 
symptoms at present time). Data analysed by Mann-Whitney U test and displayed as mean 







iv. Effects of MiRNA Overexpression on Cellular Respiration 
Chapter 6 also detailed a glycolytic shift in HUVECs overexpressing miR-126-3p and a similar 
trend in those overexpressing miR-93-5p, relating this to the musculoskeletal symptoms 
associated with these miRNAs. While other trends were apparent, overexpression of none 
of the other miRNAs yielded significant differences compared to controls (app. figure iii). 
Although miR-320a and miR-30d-5p appeared to increase basal OCR, this was not 
significant (p=0.315 and p=0.161) nor was it so at maximal OCR (p=0.316 and p=0.066). 
Overexpression of miR-3148 produced no discernible effect on OCR (basal p=0.662, 
maximal p=0.919). Moreover, none of these miRNAs affected basal (3148 p=0.147; 320a 




The statistics provided here were produced by independent samples t-test; no significance 






App. Figure iii. Seahorse bioanalysis of all miRNA overexpression constructs. HUVECs at 
p3 were transduced with either miRNA lentivirus or control pLL3.7 lentivirus at 80% 
transduction efficiency. Seahorse bioanalysis was performed using Seahorse Xfp Cell Mito 
Stress Test, with HUVECs plated at p5-7. Basal OCR (A), maximal OCR (B), basal ECAR (C) 
and maximal ECAR (D) were recorded, providing a profile of cellular respiration (E). 
Statistical analysis was performed using one-way ANOVA and independent samples t-test. 
N=3 in duplicate, n=2 for miR-93-5p constructs. * denotes p≤0.05. 
 
 




The attached publications were produced using data or techniques generated during the 
course of this project. Briefly, the first research article by Edwards et al. communicates 
much of the data from chapter 3 pertaining to QRISK3 scores and EMV abundance in SLE, 
while the second research article by Langford-Smith et al. utilises techniques such as 
Seahorse bioanalysis to interrogate the function of endothelial progenitor cells in vitro. The 
final article, a review article, provides more information on endothelial damage and repair 
in conditions associated with high cardiovascular risk. 
 
 
 
